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1 SUMMARY 
Increasing evidence indicates that Prostaglandin E2 (PGE2) promotes lung tumor growth 
by stimulating prostaglandin E receptor type 4 (EP4) signalling with subsequent 
enhancement of cellular proliferation, metastasis and suppression of immune responses. 
However, the role of other EP receptors in cancer is still not known. We hypothesized that 
prostanoid receptors other than the EP4 receptor might be involved in progression of Lung 
cancer.  
 
We analyzed the expression profile of EP receptors in lung adenocarcinoma cell lines A549 
and H1299 by using RT-PCR, western blotting and immunofluorescence. All four EP 
receptors were found to be expressed in both cell lines. While EP1 and EP2 receptors were 
localized on both cell and nuclear membrane, expression of EP3 and EP4 receptors was 
limited to the cell membrane. 
 
The EP4 receptor antagonist, L-161982 and the EP1 receptor antagonist SC-51322 
inhibited proliferation of both NSCLC cell lines. EP2 and EP3 receptor blockers did not 
inhibit proliferation. SC-51322 did not show any effect on cAMP levels in A549. 
Interestingly, it led to a decrease in intracellular calcium levels suggesting a contribution of 
calcium signaling to proliferation of cancer cells.  
 
The anti-proliferative effects of EP1 receptor inhibition was proved to be largely due to a 
decrease in intracellular calcium levels that may subsequently alter downstream signaling 
events such as phosphorylation of the Extra cellular Regulated Kinase (ERK). In our 
investigation, we found that inhibition of EP1 receptor by employing the selective inhibitor 
SC-51322, did not elicit an increase in intracellular calcium, reduced ERK phosphorylation 
and attenuated proliferation of A549 and H1299 cells. Furthermore, SC-51322 inhibited 
migration of A549 cells in presence of FCS and the EP1 receptor specific agonist 17-P-T-
PGE2. 
 
Taken together, this study supports a central role of EP1 receptor in progression and 
migration of A549 cells. Investigating the signaling pathway downstream to EP1 receptor 
will provide us with a better understanding of the contribution of this pathway in lung cancer 
and a novel therapeutic opportunity for the treatment of NSCLC. 
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2 ZUSAMMENFASSUNG 
 
Zunehmende Hinweise zeigen, dass Prostaglandin E2 (PGE2) Lungentumorwachstum 
fördert, indem es Prostaglandin E-Rezeptor Typ 4 (EP4) stimuliert, was eine anschließende 
Erhöhung der zellulären Proliferation, Metastasierung und Unterdrückung von 
Immunantworten zur Folge hat. Jedoch ist die Rolle der anderen EP-Rezeptoren in 
Krebszellen noch unbekannt. Wir stellten die Hypothese auf, dass abgesehen vom EP4-
Rezeptor noch andere Prostanoidrezeptoren im Fortschreiten von Lungenkrebs beteiligt 
sein könnten. 
 
Wir untersuchten die Expression von EP-Rezeptoren in den aus Lungen stammenden 
Adenokarzinom-Zelllinien A549 und H1299 mit RT-PCR, Western Blot und 
Immunfluoreszenz. Es konnte nachgewiesen werden, daß alle vier EP-Rezeptoren in 
beiden Zelllinien exprimiert werden. Während EP1 und EP2-Rezeptoren auf Zell- und 
Kernmembran gefunden werden konnten, war die Expression von EP3 und EP4-
Rezeptoren auf die Zellmembran beschränkt. 
 
Der EP4-Rezeptor-Antagonist, L-161982 als auch der EP1-Rezeptor-Antagonist SC-51322 
inhibierte die Proliferation von beiden NSCLC-Zelllinien. EP2 und EP3-Rezeptor-Blocker 
hingegen konnten die Proliferation nicht hemmen. SC-51322 zeigte keinen Einfluss auf den 
cAMP-Level in A549 Zellen. Interessanterweise führte dies zu einer Abnahme des 
intrazellulären Kalziumspiegels, was auf eine Beteiligung des Calcium-Signalwegs bei der 
Proliferation von Krebszellen schließen läßt. 
 
Die antiproliferative Wirkung von EP1-Rezeptor-Hemmung erwies sich als Folge  der 
Abnahme des intrazellulären Calcium-Spiegels, die nachgeschaltete Signalwege, wie die 
Phosphorylierung der „Extrazellular Regulated Kinase“ (ERK) verändern können. In 
unserer Untersuchung haben wir festgestellt, dass die Inhibition des EP1-Rezeptors durch 
die Verwendung des selektiven Inhibitors SC-51322, keine Erhöhung des intrazellulären 
Calciumlevels hervorruft,  auch die ERK-Konzentration verringert und die Proliferation von 
A549 und H1299-Zellen hemmt. Darüber hinaus inhibiert SC-51322 die Migration von 
A549-Zellen in Gegenwart von FCS und dem EP1-rezeptorspezifischen Agonisten 17-P-T-
PGE2. 
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Zusammengefasst unterstützt diese Studie eine zentrale Rolle des EP1-Rezeptors in der 
Progression und der Migration von A549-Zellen. Die Untersuchung des dem EP1-Rezeptor 
nachgeschalteten Signalwegs wird uns ein besseres Verständnis der Rolle dieses 
Signalwegs bei Lungenkrebs und eine neue therapeutische Möglichkeit zur Behandlung 
von NSCLC bieten. 
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3 INTRODUCTION 
Lung cancer is the leading cause of cancer deaths for both men and women worldwide. 
The 5 year survival rate is ~14%, primarily due to inability to detect the disease early [1]. 
Lung cancer is the most common cancer in the world. Approximately 1.61 million cases, 
representing 12.7 % of all new cancers and 1.38 million deaths (18.2 % of the total) are 
from lung cancer. Lung cancer is now the fourth most frequent cancer of women with 8.5% 
of all cancers and the second most common cause of death from cancer with 12.8% of the 
total [2]. More than 70% of people diagnosed with lung cancer are the people above 65 
years making it a disease of elderly while less than 3% of lung cancers occur in people less 
than 45 years of age [3].  
 
Majority of cases now occur in developing countries. Lung cancer incidences are at high 
rates in Central-eastern and Southern Europe, Northern America and Eastern Asia. Very 
low rates are still estimated in Middle and Western Africa [4]. The highest incidence rate is 
observed in Northern America (where lung cancer is now the second most frequent cancer 
in women), and the lowest in Middle Africa (15th most frequent cancer) [5]. Lung cancer is 
expected to rise in those countries with high incidence of tobacco smoking though recent 
clinical advances like low-dose computed tomography screening and advancements in 
surgery and radiation may change this outcome [6]. 
 
The increase in fall of lung cancer incidences can be observed in many developing 
countries following public education about the dangers of smoking and introduction of 
effective smoking cessation programs. 
 
According to 2009 estimates, lung cancer is the most commonly diagnosed cancer world 
wide among all the other cancers (Figure 1). 
 
3.1 Etiology of lung cancer 
3.1.1 Smoking 
 
The most documented causal relationship in biomedical research has been the role of 
cigarette smoking in causing lung cancer, accounting for about 90% of lung cancer cases 
[7].  
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   Figure 1: The American Cancer Society estimates 2009 
                     
Cigarette smokers smoking one pack of cigarettes per day are considered to have a 25 
times higher risk of developing lung cancer than a non-smoker. Whereas, pipe and cigar 
smokers have 5 times higher risk than that of a non-smoker. Earliest links between 
smoking and lung cancer were reported by german scientists [6]. Epidemiologic studies in 
Britain and the United States using the case control methods had demonstrated that 
cigarettes smoking was strongly associated with the risk of lung cancer [8], [9] and these 
results were further, corroborated by American Cancer Society.  
3.1.2 Passive smoking 
 
Involuntary inhalation of tobacco smoke by nonsmokers, has also been found to cause lung 
cancer. Two studies published in 1981 ascribed that the inhalation of second hand smoke 
or environmental tobacco smoke led to an increase in the risk of lung cancer in passive 
smokers [6], [10]. Additionally, a review by the National Research Council has concluded 
that there is a chance of developing lung cancer by 30% in spouses who are married to 
cigarette smokers than spouses of non-smokers [6].  
         INTRODUCTION 
 
3 
3.1.3 Asbestos fibers 
 
Retrospective cohort studies by Doll et al in 1955 [11] have established asbestos also as 
one of the leading causes of lung cancer. Increased exposure to asbestos is directly 
proportional to increased risk of lung cancer [12]. The mechanism of how asbestos 
exposure leads to cancer whether by acting as a carcinogen itself or by causing chronic 
inflammation is to be studied. Though asbestos and cigarette smoking are independent 
causes of lung cancer, in combination, they act synergistically to increase the risk of lung 
cancer. Cigarette smoking increases the risk of cancer associated with asbestos exposure 
probably by retention of asbestos fibres [6], [13].  
3.1.4 Radon gas 
 
Radon is an inert gas that is produced naturally from radium in the decay series of uranium. 
Two of the decay products of radon emit alpha particles that, by virtue of their high energy 
and mass, can cause damage to the DNA of cells of the respiratory epithelium. Radon gas 
is a well-known cause of lung cancer, with an estimated 12% of lung-cancer deaths 
attributable to radon gas. On average, indoor exposures to radon for the general population 
are much less than those received by occupational groups such as uranium miners. 
Cigarette smoking and radon decay products synergistically influence lung cancer risk in a 
supra additive manner [6]. 
3.1.5 Familial predisposition 
 
Numerous studies have shown that relatives of both non-smoking and smoking people are 
prone to lung cancer. Recent studies have identified that human chromosome 15 contains 
genes coding for proteins that interact with nicotine and other tobacco toxins [6]. 
3.1.6 DNA repair  
 
DNA repair capacity has now been examined as a specific risk factor for lung cancer. The 
lower the DNA repair capacity, the greater the risk of lung cancer from smoking [14]. 
Although much research remains to be done to delineate the link between those two, the 
evidence suggests that this is a promising lead.  
3.1.7 Lung diseases 
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Substantial body of evidence shows that acquired lung diseases like Chronic Obstructive 
Pulmonary Disease (COPD) and fibrotic disorders increase the susceptibility of lung cancer 
by four to six fold [6]. 
3.1.8 Prior history of lung cancer 
 
Survivors of lung cancer have a greater risk of developing a second lung cancer than the 
general population. Survivors of non-small cell lung cancers (NSCLCs) have an additive 
risk of 1% -2 % per year where as 6% per year for the survivors of small cell lung cancers 
(SCLCs) [6], [15]. 
3.1.9 Air pollution 
 
The percentage of lung cancer deaths because of air pollution is as low as 1% of all cancer 
deaths, experts believe that it may get equivalent to death percentage of passive smoking 
upon prolonged exposure to air pollutants [6].  
3.2 Lung cancer classification  
 
Carcinomas of the lung, also known as primary lung tumors, are classified based on their 
histological appearance and tissue of origin or alternatively according to the predominant 
cell type. The histo-pathological type is connected with tumor behaviour and patients’ 
prognosis [16]. 
 
The two main histological groups imply small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC) [16], [17].  
 
These two types of cancers grow and spread in different ways and may have different 
treatment options. So, a distinction between these two types is important. SCLC comprises 
about 20% of lung cancers and is the most aggressive, rapidly growing of all lung cancers. 
SCLCs are strongly related to cigarette smoking, with only 1% of these tumors occurring in 
non-smokers. SCLCs have a greater metastatic potential and are most often discovered 
after they have spread extensively.  
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Table 1 Classification of Lung tumors 
 
1 Epithelial Tumors 
   1.1. Benign 
      1.1.1. Papillomas 
            1.1.1.1. Squamous cell papilloma Exophytic Inverted 
            1.1.1.2. Glandular papilloma 
            1.1.1.3. Mixed squamous cell and glandular apilloma 
      1.1.2. Adenomas 
            1.1.2.1. Alveolar adenoma 
            1.1.2.2. Papillary adenoma 
            1.1.2.3. Adenomas of salivary-gland type Mucous gland adenoma Pleomorphic  
                         adenoma Others 
            1.1.2.4. Mucinous cystadenoma 
            1.1.2.5. Others 
  1.2. Preinvasive lesions 
     1.2.1. Squamous dysplasia/Carcinoma in situ 
     1.2.2. Atypical adenomatous hyperplasia 
     1.2.3. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
  1.3. Malignant 
     1.3.1. Squamous cell carcinoma Variants 
           1.3.1.1. Papillary 
           1.3.1.2. Clear cell 
           1.3.1.3. Small cell 
           1.3.1.4. Basaloid 
     1.3.2. Small cell carcinoma Variant 
           1.3.2.1. Combined small cell carcinoma 
     1.3.3. Adenocarcinoma 
           1.3.3.1. Acinar 
           1.3.3.2. Papillary 
           1.3.3.3. Bronchioloalveolar carcinoma 
                    1.3.3.3.1. Non-mucinous (Clara/pneumocyte type II) 
                    1.3.3.3.2. Mucinous 
                    1.3.3.3.3. Mixed mucinous and non-mucinous or intermediate cell type 
           1.3.3.4. Solid adenocarcinoma with mucin 
           1.3.3.5. Adenocarcinoma with mixed subtypes 
           1.3.3.6. Variants 
                    1.3.3.6.1. Well-differentiated fetal adenocarcinoma 
                    1.3.3.6.2. Mucinous ("colloid") adenocarcinoma 
                    1.3.3.6.3. Mucinous cystadenocarcinoma 
                    1.3.3.6.4. Signet-ring adenocarcinoma 
                    1.3.3.6.5. Clear cell adernocarcinoma 
     1.3.4. Large cell carcinoma Variants 
           1.3.4.1. Large cell neuroendocrine carcinoma 
                    1.3.4.1.1. Combined large cell neuroendocrine carcinoma 
                    1.3.4.2. Basaloid carcinoma 
                    1.3.4.3. Lymphoepithelioma-like carcinoma 
                    1.3.4.4. Clear cell carcinoma 
                    1.3.4.5. Large cell carcinoma with rhabdoid phenotype 
      1.3.5. Adenosquamous carcinoma 
      1.3.6. Carcinomas with pleomorphic, sarcomatoid or sarcomatous elements 
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Table 1 continued 
 
            1.3.6.1. Carcinomas with spindle and/or giant cells 
                     1.3.6.1.1. Pleomorphic carcinoma 
                     1.3.6.1.2. Spindle cell carcinoma 
                     1.3.6.1.3. Giant cell carcinoma 
            1.3.6.2. Carcinosarcoma 
            1.3.6.3. Pulmonary blastoma 
            1.3.6.4. Others 
      1.3.7. Carcinoid tumor 
           1.3.7.1. Typical carcinoid 
           1.3.7.2. Atypical carcinoid 
      1.3.8. Carcinomas of salivary-gland type 
            1.3.8.1. Mucoepidermoid carcinoma 
            1.3.8.2. Adenoid cystic carcinoma 
            1.3.8.3. Others 
      1.3.9. Unclassified carcinoma 
2 Soft Tissue Tumors 
    2.1 Localized fibrous tumor 
    2.2 Epithelioid hemangioendothelioma 
    2.3 Pleuropulmonary blastoma 
    2.4 Chondroma 
    2.5 Calcifying fibrous pseudotumor of the pleura 
    2.6 Congenital peribronchial myofibroblastic tumor 
    2.7 Diffuse pulmonary lymphangiomatosis 
    2.8 Desmoplastic small round cell tumor 
    2.9 Other 
3 Mesothelial Tumors 
   3.1 Benign 
      3.1.1 Adenomatoid tumor 
   3.2 Malignant 
      3.2.1 Epithelioid mesothelioma 
      3.2.2 Sarcomatoid mesothelioma 
            3.2.2.1 Desmoplastic mesothelioma 
      3.2.3 Biphasic mesothelioma 
      3.2.4 Other 
4 Miscellaneous Tumors 
   4.1 Hamartoma 
   4.2 Sclerosing hemangioma 
   4.3 Clear cell tumor 
   4.4 Germ cell neoplasms 
      4.4.1 Teratoma, mature or immature 
      4.4.2 Malignant germ cell tumor 
   4.5 Thymona 
   4.6 Melanoma 
   4.7 Others 
5 Lymphoproliferative Disease 
   5.1 Lymphoid interstitial pneumonia 
   5.2 Nodular lymphoid hyperplasia 
   5.3 Low-grade marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue 
   5.4 Lymphomatoid granulomatosis 
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Table 1 continued 
 
6 Secondary Tumors 
7 Unclassified Tumors 
8 Tumor-like Lesions 
   8.1 Tumorlet 
   8.2 Multiple meningothelioid nodules 
   8.3 Langerhans cell histiocytosis 
   8.4 Inflammatory pseudotumor (Inflammatory myofibroblastic tumor) 
   8.5 Organizing pneumonia 
   8.6 Amyloid tumor 
   8.7 Hyalinizing granuloma 
   8.8 Lymphangioleiomyomatosis 
   8.9 Multifocal micronodular pneumocyte hyperplasia 
   8.10 Endometriosis 
   8.11 Bronchial inflammatory polyp 
   8.12 Others 
 
The new World Health Organization classification of lung tumors. E. Brambilla, W.D. Travis, T.V. 
Colby, B. Corrin, Y. Shimosato.  ERS Journals Ltd 2001. 
 
NSCLC are the most common lung cancers, accounting for about 80% of all lung cancers. 
NSCLC can be divided into three main types that are named based upon the type of cells 
found in the tumor.  
3.2.1 Adenocarcinomas 
 
Adenocarcinoma is the predominant histological subtype of lung carcinoma comprising 
50% of lung cancers. It is the most prevalent form of lung cancer in younger males (< 50 
yrs old), in women of all ages, in never smokers, and in former smokers. Adenocarcinomas 
are histologically heterogenous, making them difficult to sub-classify. Only a minority of 
cases like acinar, papillary and solid adenocarcinoma show a pure histological pattern. 
Most adenocarcinomas arise in the outer, or peripheral, areas of the lungs.  
Bronchioloalveolar carcinoma is a subtype of adenocarcinoma that frequently develops at 
multiple sites in the lungs and spreads along the preexisting alveolar walls [16], [18].  
3.2.2 Squamous cell carcinomas  
 
Squamous cell carcinomas are next most prevalent to adenocarcinomas. This type is 
mainly located centrally, with common segmental or lobar collapse, and tumors are often 
larger than 4cm in diameter. This histological type, correlated with a smoking history, is 
more prevalent in men than women. At present, they account for about 30% of NSCLC. 
They are also known as epidermoid carcinomas [18]. 
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3.2.3 Large cell carcinoma 
 
Large cell carcinomas, sometimes referred to as undifferentiated carcinomas, are the least 
common type of NSCLC with early metastasis to the mediastinum and brain. It is a fast-
growing form that grows near the surface of the lung. They are found in approximately 
10%-15% of lung cancer cases.  
 
Other rare types of cancer may be found, although they represent a very small percentage  
(less than 5%) of the total number of lung cancer cases, which includes adenosquamous 
carcinoma, sarcomatoid carcinoma, carcinoid tumor, and salivary gland tumors [19], [20]. 
3.3 Lung cancer symptoms and signs 
 
Symptoms of lung cancer are not always easy to identify and sometimes there may not be 
any symtoms. Symptoms of lung cancer vary depending upon the severity of it. The 
following kinds of symptoms can be observed in lung cancer patients –  
 
No symptoms: In up to 25% of patients with lung cancer, it is first discovered on a routine 
chest X-ray or CT scan as a solitary small mass sometimes often called a coin lesion, as in 
a two-dimensional X-ray or CT scan, the round tumor resembles a coin. These patients 
with coin lesions often report no symptoms at the time the cancer is discovered. 
 
Symptoms related to the cancer:  Breathing problems like cough, shortness of breath, 
wheezing leading to chest pain and coughing up blood result due to the growth and 
invasion of cancers in to the surrounding tissues. Pancoast’s syndrome (shoulder pain etc) 
or paralysis of the vocal cords occurs when cancer invades nerves. Invasion of 
oesophagus leads to dysphagia and invasion of airways leads to the collapse of that 
particular portion of lung leading to infections like pneumonia and abscesses [19]. 
 
Symptoms related to metastasis: Metastatic cancers when they are in bones produce 
excruciating pains in joints and the places where there is an involvement of bone. When it 
spreads to brain, it may lead to loss of sensation to parts of body along with symptoms like 
blurred vision, seizures and symptoms of stroke [19].  
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Paraneoplastic symptoms: Lung cancers are frequently accompanied by symptoms that 
result from production of hormone-like substances by the tumor cells. Paraneoplastic 
syndromes seen in SCLC are over secretion of cortisol by adrenal glands leading to 
cushing’s syndrome. Where as in NSCLC, it leads to elevated levels of calcium in the 
bloodstream [20]. 
 
Nonspecific symptoms: Nonspecific symptoms as observed with many cancers are also 
seen in lung cancers. They include weight loss, weakness, and fatigue. Psychological 
symptoms such as depression and mood changes are also common [20]. 
3.4 Staging of lung cancer 
 
Methods to diagnose and stage the disease in the individual patient are essential for 
accurate prognosis and planning the optimal treatment. It helps to standardize a general 
language for researchers and clinicians and is used to stratify patients in treatment 
categories and to determine their prognosis.  
 
Staging of lung cancer is mainly based on the lesion size, local and regional lymph node 
spread as well as presence or absence of metastases (Kumar et al 2007 Robbins basic 
pathology, 8th edition). Staging is mainly done on the results of pulmonary X-rays, CT-
scans of the thorax and upper abdomen, bronchoscopy, and, in elective cases, 
mediastinoscopy basing on the recommendations from Union Internationale Contre le 
Cancer (UICC). The classification is based on the size, spread and spread of the tumor in 
relation to main bronchus or thoracic wall, node involvement and metastasis [21], [22] and 
the identification method is called the TNM system. The TNM system is used to determine 
the stage (numbered 0 to IV) of the tumor. The four stages, based on the TNM 
classification described below, provide a consistent and reproducible classification for 
describing the extent of disease [16], [23]. 
 
Since the small cell lung cancer (SCLC) is overt metastatic at diagnosis, the TNM system is 
not recommended for its management.  
 
Hence, these cancers are broadly classified into two categories, extensive and limited 
stage disease. Limited stage disease is defined as cancer confined to the hemithorax of 
origin, the mediastinum, and the supraclavicular nodes. With extensive stage disease, the 
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tumor is widespread; patients with distant metastases are always included in this group 
[16]. 
 
Lung Cancer Staging 
Stage     Tumor    Lymph      Metastasis     Definition 
                              Nodes    
   0          Tis           N0                M0              Tis:   Carcinoma In situ 
                                                                       N0:   No regional lymph node metastasis 
                                                                       M0:  No distant metastasis 
   IA         T1a          N0                M0              T1:   Tumor ≤ 3 cm, surrounded by lung or visceral pleura, 
                                                                                  Without invasion more proximal than the lobar bronchus 
                                                                       T1a: Tumor ≤ 2 cm 
               T1b          N0                M0              T1b: Tumor > 2cm but ≤ 3 cm 
   IB         T2a          N0                M0              T2:   Tumor > 3 cm but ≤ 7 cm or tumor involves main bronchus, 
                                                                                ≥ 2 cm distal to carnia; invadees visceral pleura; associated       
                                                                               with atelectasis or obstructive pneumonitis extending to hilar  
                                                                                region but not entire lung 
                                                                        T2a: Tumor > 3 cm but ≤ 7 cm 
   IIA         T2b          N0               M0              T2b: Tumor > 5 cm but ≤ 7 cm 
                T1a          N1               M0               N1 : Metastasis in ipsilateral peribronchial and/or hilar lymph  
                                                                                nodes and intrapulmonary nodes by direct extension 
                T1b          N1               M0                
                T2a          N1               M0 
   IIB         T2b          N1               M0 
                 T3            N0              M0                T3:  Tumor > 7 cm or directly invades parietal pleural, chest  
                                                                                 wall,diaphram,phrenic nerve,mediastinal pleura,parietal  
                                                                                 pericardium; or main bronchus < 2 cm distal to cornia; or  
                                                                                 associated atelectasis or obstructive pneumonitis of entire  
                                                                                 lung or seperate tumor nodule(s) in same lobe 
  IIIA         T1a            N2              M0                N2: Metastasis in ipsilateral mediastinal and/or subcarnial  
                                                                                 lymphnode(s) 
                T1b            N2              M0 
                T2a            N2              M0 
                T2b            N2              M0 
                T3              N1              M0 
                T4              N2              M0                 T4: Tumor of any size invades mediastinum, heart, great  
                T4              N1              M0                       vessels, trachea, recurrent laryngeal nerve, esophagus,  
                                                                                 vertebral body, carnia, seperate tumor nodule(s) in  
                                                                                 different ipsilateral lobe 
   IIIB       T1a            N3               M0                N3: Metastasis in contralateral lymphnode(s), or  
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                                                                                 supraclavicular lymph node(s) 
               T1b            N3               M0 
               T2a            N3               M0 
               T2b            N3               M0 
     Stage     Tumor    Lymph      Metastasis     Definition 
                                   Nodes    
                       T4          N2               M0              
                       T4          N3               M0 
       IV           Any T    Any N            M1a            M1: Distant metastasis 
                                                                           M1a: Separate tumor nodule(s) in a contra lateral lobe; tumor  
                                                                                     with pleural nodules or malignant pleural (or pericardial)  
                                                                                     effusion  
                    Any T    Any N              M1b           M1b: Distant metastasis (in extra thoracic organs) 
 
Table 2: Lung Cancer Staging System.  
Developed by the American Joint Committee on Cancer, 7th edition published 2009, table revised from 
Savai, 2006.  
 
SCLC are staged using a two-tiered system: 
 
• Limited-stage (LS) SCLC refers to cancer that is confined to its area of origin in the 
chest. 
 
• In extensive-stage (ES) SCLC, the cancer has spread beyond the chest to other parts 
of the body. 
3.5 Treatment for lung cancer 
 
The aim of treatment is to cure and prolong life. Furthermore, metastasis is an important 
part in determining curative intention or palliative treatment to reduce the suffering of the 
patients. Palliative therapy, to improve quality of patient’s life, is the primary concern for 
advanced disease [24].  
 
Treatment of lung cancer can involve surgery, chemotherapy, or radiation therapy, as well 
as combinations of all these treatments depending on the location of the tumor and severity 
of the cancer. 
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3.5.1 Surgery:  
 
Though there are chances of remission, surgery remains to be one of the main cures for 
about one third of patients with NSCLC (stages I, II, and a limited group of patients with 
stage IIIA) who have surgically resectable disease. In SCLC, however, surgery is not 
feasible, since most patients have either locally advanced disease or distant metastases. 
 
There are three surgical procedures commonly used to treat lung cancer: wedge resection, 
or segmentectomy (in which a small section of the lung is removed); lobectomy (in which 
an entire section is removed); pneumonectomy in which entire lung is removed [25], [26].  
3.5.2 Radiation: 
 
Radiation therapy can be given as a curative, palliative or as an adjuvant therapy in 
combination with surgery or chemotherapy. In this therapy, dividing cancer cells are killed 
using high energy radiation (eg: X-rays etc). Radiation therapy may be employed as a 
treatment for both NSCLC and SCLC.  
 
Brachytherapy is a term used to describe the use of a small pellet of radioactive material 
placed directly into the cancer or into the airway next to the cancer. This is usually done 
through a bronchoscope. Radiotherapy elicits responses in about 90% of patients with 
SCLC and in about 50% of those with NSCLC [27], [28]. 
3.5.3 Chemotherapy:  
 
Drugs are used to stop the growth of cancer cells either by killing them or preventing their 
cell division. Both NSCLC and SCLC can be treated by chemotherapy. Chemotherapy may 
be given alone, as an adjuvant to surgical therapy, or in combination with radiotherapy. So 
far, the platinum-based drugs have been the most effective in treatment of lung cancers. 
For most SCLCs, chemotherapy is the treatment of choice where as for NSCLCs, 
chemotherapy prolongs the survival in many cases [29]. 
 
New drugs like taxanes (paclitaxel and docetaxel), camptothecins (topotecan and 
irinotecan), new anti-metabolites (such as gemcitabine and difluorodeoxycytidine) and anti-
tubulin agents (vinorelbine) have shown promise in the management of NSCLC [30], [31], 
[32]. 
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3.5.4 Targeted therapy:  
 
Targeted therapy drugs more specifically target cancer cells, resulting in less damage to 
normal cells than general chemotherapeutic agents. Erlotinib and gefitinib target a protein 
called the epidermal growth factor receptor (EGFR) that is important in promoting the 
division of cells. This protein is found at abnormally high levels on the surface of some 
types of cancer cells, including many cases of non-small cell lung cancer. Additionally,, 
patients with NSCLC can be treated with Cetuximab as an antibody based targeted therapy 
which binds specifically to EGFRs [33].  
3.6 Prostanoid Signaling  
 
Prostanoids are the cyclooxygenase metabolites of arachidonic acid. The cyclooxygenases 
COX-1 and COX-2 are the rate limiting enzymes in the synthesis of all prostanoids from 
arachidonic acid [34]. While COX-1 is expressed constitutively in a subset of cell types, 
COX-2 is highly regulated by transcriptional and post-translational mechanisms in response 
to a plethora of stimuli. Induction of COX-2 triggers the synthesis of different prostanoids 
that play essential roles in many physiological processes and responses, such as 
inflammation, pain, fever, and platelet aggregation. Cyclooxygenases catalyze a two-step 
reaction that converts arachidonic acid to prostaglandin H2 (PGH2) which in turn serves as 
the precursor for the synthesis of all biologically active prostanoids: PGD2, PGE2, PGF2, 
prostacyclin (PGI2), 15-deoxy-D12, 14-PGJ2, and thromboxane A2 [35].  
 
In general, basing on the type of G-protein activated by different receptors, prostanoid 
receptors can be grouped into three categories. The first category includes the relaxant 
receptors, IP, EP2, EP4, and DP receptors activating Gs which stimulates cAMP production 
by adenylate cyclase. The second category includes the contractile type of prostanoid 
receptors TP, EP1, and FP activate the G-protein Gq, mediating enhanced intracellular 
Ca2+ levels by influencing phosphatidylinositol turnover. Finally, the last group contains a 
lone receptor EP3, which inhibits adenylate cyclase acting via G-protein Gi. 
 
A comprehensive work of the past decade substantiated by targeted molecular designs 
derived from preclinical in vitro and in vivo studies, has proved that COX-2 and the sub-set 
of prostanoids and their receptors playing role in oncogenic pathways.  
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       Y. Sugimoto et al., Progress in Lipid Research 2000 
         
Table 3: Properties of mouse prostanoid receptors  
 
In general physiology, the TXA2 prostanoid receptor designated as ‘TP’ has an important 
role in hemostasis, platelet aggregation and smooth muscle contraction. TP is also 
implicated in the pathogenesis of athrosclerosis and myocardial infarcts.  Prostaglandin F2α 
binds to the receptor FP and plays role in hypertrophic cell growth, interleukin synthesis 
and uterine contraction where as prostaglandin D2 binds to the receptor DP and inhibits 
platelet aggregation and causes relaxation of both vascular and non-vascular smooth 
muscle cells similar to IP (Prostaglandin I2 receptor). PGE2 and its receptor regulation are 
discussed in a separate section. 
 
3.7 Prostanoid signaling in Cancer 
 
COX2 induced tumorigenesis was first reported by Liu et al [36] using mouse models. They 
observed hyperplasia and carcinoma in epithelial cells, higher expression of COX-2 protein 
along with increased PGE2 levels, when they inserted COX-2 gene downstream to murine 
mammary tumor promoter. This is the only study demonstrating a clear role of COX-2 in 
tumor initiation. Transgenic studies indicate that COX-2 over expression is insufficient for 
tumor induction but sufficient to transform epidermis in to an auto promoted state causing 
sensitization of genotoxic carcinogens in it. These studies support the role of COX-2 in 
tumor promotion rather than initiation [37].  
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The role of COX-2 in tumor progression is further supported by Oshima et al [38] in 
colorectal tumor models. In their studies, they observed a decrease in the number and size 
of the intestinal polyps when there is a prostaglandin synthase 2 (Ptgs2) null mutation. 
These results provide direct genetic evidence to the role of COX-2 in tumorigenesis and 
indicate that COX-2-selective inhibitors can be a novel class of therapeutic agents for 
colorectal polyposis and cancer [38].  
 
Several studies related to the downstream molecules of COX-2 also support its role in 
carcinogenesis. It has been observed that, PGE2 being most important downstream 
effector of COX-2, gets up regulated in cancers. 
 
Synergistic effects of Non-Steroidal Anti Inflammatory Drugs (NSAIDs) and conventional 
chemotherapeutic agents on tumor growth and development has been shown by Teicher et 
al [39]. In these studies, authors used Lewis lung carcinoma model as a model of NSCLC. 
Combinations of a COX inhibitor with chemotherapeutic agents such as cisplatin, 
carmustine, melphalan and cyclophosphamide resulted in tumor growth delay and a 
decreased lung metastases [39]. 
 
In the past few years, the role of COX-2 has been reported in numerous human solid 
tumors showing that over-expression of COX-2 is not limited to colon cancer but can be 
considered as a common feature in various other epithelial tumors [40]. 
3.8 PGE2 regulation and its receptors  
 
Steady state cellular levels of PGE2 depend on the relative rates of COX-2/PGE synthase 
dependent biosynthesis and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) 
dependent degradation. For example, cytosolic or microsomal PGE2 synthases can 
convert PGH2 to PGE2. Two cytosolic PGE2 synthases called cytosolic glutathione 
transferases (GSTM2-2 and GSTM3-3) catalyse the conversion of PGH2 to PGE2 in the 
human brain. [41] The two microsomal PGE2 synthases characterised to date are 
mPGES1 and mPGES2. mPGES1 exhibits a higher catalytic activity than other PGES 
isomerases, indicating that it probably plays a key role in the synthesis of PGE2 from 
PGH2. 15-PGDH, a prostaglandin degrading enzyme, catalyses oxidisation of the 15(S)-
hydroxyl group of PGE2 to yield an inactive 15-keto PGE2 [40]. 
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PGE2 is a common ligand for a group of membrane receptors EP1, EP2, EP3 and EP4   
belonging to the family of seven transmembrane G-protein coupled receptors showing a 
tissue specific expression and distribution [42], [43].  
3.8.1 EP1 Receptor 
 
EP1 receptor with a molecular weight of 43 KDa contains 405 amino acids. EP1 receptor 
expression profile in mice ranges various tissues like epidermis of the skin, sebaceous 
gland, kidney, bladder, blood vessel, and in the lung. On ligand induced activation, EPI 
induces an influx of extracellular calcium through voltage independent, Mn2+ impermeable 
calcium channel along with release of calcium from intracellular stores in a PLC dependent 
manner (Figure 3). 
 
Interestingly in a study by Katoh & Watabe et al [44], EP1 receptor is desensitized with 
PKC phosphorylation by dissociating with G-protein.  A lowered EP1 mRNA expression 
was observed Chinese hamster ovary cells over expressing EP1 on treatment with TPA (a 
potent PKC activator) for 24hours. However, Funk [45] observed an induction of EP1 
mRNA two days after TPA treatment.   
 
The role of Src/EGFR/Stat3/Akt downstream to EP1 receptor, resulting in PGE2 dependent 
cell growth and invasion of human cholangiocarcinoma has been reported by Han & Wu 
[46], [47]. EP1 mediated ERK activation in squamous cell carcinoma of NSCLC has been 
reported by Krysan et al [48].  
 
In normal physiology, EP1 is very important in the brain.  When EP1 receptor was 
antagonised, mice were protected against the brain injury [49]. A reduced social interaction 
and an increased aggressiveness was observed in EP1 receptor deficient mice [50]. 
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             modified from Tennis et al., Translational Research, February 2010 
 
Figure 2: Prostanoid Signaling Pathway  
 
Involvement of EP1 in mediating pain response/sensitivity is also suggested by Stock et al 
[51] not only in the acetic acid–induced writhing test, but also in the 2-phenyl-1, 4-
benzoquinone–induced (PBQ-induced) stretch assays, as reduced responses were 
observed in their EP1−/− mice. Their pain sensitivity responses were reduced by 
approximately 50%, and this reduction in the perception of pain was virtually identical to 
that in WT mice using piroxicam, a COX inhibitor. EP1−/− mice showed a hyperalgesic 
action in the hot plate test and the hyperalgesia was alleviated by PGE2 in a dose-
dependent manner [52]. 
 
EP1 receptor propagates neurotoxicity and hence, selective blockade could be considered 
as a potential preventive and/or therapeutic tool against ischemic/hypoxic neurological 
conditions [53]. 
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Harris et. al., Trends in immunology, 2002 
Figure 3: Signaling through EP receptors  
EP-Receptors are rhodopsin-type receptors with seven transmembrane-spanning domains. The four main 
subtypes of EP-R (EP1–EP4) are coupled to different G proteins and use different second messenger 
signaling pathways. EP1 is coupled to Gq/p and ligand binding results in an increase in the level of 
intracellular calcium. EP2 and EP4 are coupled to Gs proteins and induce the expression of cAMP, which 
leads to gene regulation. The three isoforms of EP3 (α, β and γ) are coupled primarily to Gi and are most 
often inhibitory to cAMP. (There is some evidence that additional signaling cascades might be activated by 
EP3 binding.) Abbreviations: AC, adenylate cyclase; DAG, diacylglycerol; IP3, inositol triphosphate; PIP2, 
phosphatidylinositol diphosphate; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C.  
 
PGE2-EP1 signaling has been demonstrated to play crucial roles in suppression of 
myoelectrical activity of gastric smooth muscles and inhibition of gastric emptying, putting 
forward EP1 as an obvious target for drugs that control gastric emptying [54]. 
 
EP1 deficient mice have reduced systolic blood pressure [51], develop insensitivity to pain 
[55]. Important role of EP1 in inflammation makes it a suitable target for both inflammation 
and cancer. In stomach, PGE2 failed to induce bicarbonate ion in EP1 deficient mice [56] 
where as in Leydig cell progenitors, EP1 mediates IL-1β expression [57].  
3.8.2 EP2 Receptor 
 
EP2 receptor couples to Gαs to increase intracellular cAMP levels which binds to regulatory 
subunits of cAMP dependent protein kinase (PKA) leading to phosphorylation of PKA 
substrates like cAMP-response element binding protein (CREB) at Ser 133 which ultimately 
results in the translocation of CREB co-activators from cytosol to nucleus [58]. 
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In normal physiology, EP2 receptor is known to play a role in female reproductive system. 
A reduced number of ovulation and a lower fertilization rate have been observed in EP2 
deficient female mice [59].  Kennedy et al found EP2 -/- female mice have consistently 
fewer pups than WT and detected slightly impaired ovulation and a reduction in fertilization 
concluding the failure in COX-2 deficient mice is due to dysfunction of the EP2 receptor 
[60]. Whether polymorphisms in the EP2 receptor are associated with infertility in humans 
remains to be determined. 
 
In the lung, EP2 receptor mediates broncho-dilating actions of PGE2 [61]. In mice lacking 
EP2 receptor, salt sensitive hypertension develops [60] and lowering of blood pressure by 
PGE2 is impaired [62]. 
 
For instance, upon PGE2 or butaprost (EP2 receptor specific PGE2 analog) administration 
intravenously, only wildtype but not EP2 -/- mice became hypotensive. Surprisingly, EP2 -/- 
mice became hypertensive with PGE2 indicating the absence of EP2 abolishes the ability 
of the vasculature to dilate in response to PGE2 and unmasks the contractile response via 
vasoconstrictor EP receptor(s) [60]. In addition, PGE2- EP2 signaling is also reported to 
contribute to the spinal inflammatory hyperalgesia in the zymosan, a peripheral 
inflammation model [63]. Yeast extract injected subcutaneously into the paw induces 
inflammatory hyperalgesia. Although thermal and mechanical sensitization in EP2 -/- mice 
is similar to WT mice at 2 hours post injection, from 4 hours onward EP2 -/- mice recovered 
faster from hyperalgesia. These results suggest a dominant role for PGE2-EP2 signaling in 
the generation of inflammatory pain.  
3.8.3 EP3 Receptor 
 
EP3 receptor has three isoforms (EP3α, EP3β and EP3γ) in mouse and seven isoforms in 
human. EP3 receptors are coupled to Gαi and decrease intracellular cAMP levels by 
inhibiting adenylate cyclase. Activation of EP3 also increases intracellular calcium levels by 
activation of phospholipase C (PLC) through the Gβγ subunit [64]. 
 
Mice with targeted deletion of the EP3 receptor exhibit an impaired febrile response to 
PGE2, suggesting that EP3 receptor antagonists could be effective antipyretic agents [65]. 
EP3 deficient mice were also used to determine the role of PGE2 in pain perception. EP3 
and IP were found to be the major prostaglandin receptors mediating the enhanced pain 
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response in mice pre-treated with LPS to induce COX-2 expression [66]. EP3 deficient 
mice also demonstrated that the PGE2 -EP3 pathway is an important negative modulator of 
allergic reactions. Only EP3 deficient mice were shown to develop an allergic inflammation 
that was much more pronounced than that in wtmice or mice deficient in other EP receptor 
subtypes. Conversely, an EP3-selective agonist suppressed the inflammation [65].  
 
EP3 deficient mice exhibit increased frequency of feeding during the light cycle of the day 
and develop an obese phenotype under a normal fat diet fed ad libitum. Although EP3 
deficient mice showed an increased motor activity, this did not compensate sufficiently to 
offset the increased body weight. These findings further indicate that there is a link between 
inflammatory signaling and obesity. 
 
Additionally, EP3 deficient mice were found to have impaired duodenal bicarbonate 
secretion and mucosal integrity. The presence of EP3 receptors were found to be essential 
for maintaining duodenal acid secretion and maintaining the mucosal integrity against 
luminal acid [67]. EP3 is also known to maintain blood pressure [68] and urine 
concentrations [69]. 
3.8.4 EP4 Receptor 
 
Similar to EP2 receptor signalling, EP4 also couples to Gαs and increases cAMP formation 
resulting in activation of PKA. Activated PKA phosphorylates CREB, GSK-3 and further 
leads to activation of β-catenin. EP4 also couples to Gαi decreasing cAMP and activating 
PI3K/AKT pathway. EP4 is expressed in human and mouse heart, lung, thymus, spleen, 
ileum and skin [70],[61]. In mice, PGE2 enhances bone resorption through EP4 [71]. 
 
EP4 receptor activation has been shown to have important vasodilator effects in venous 
and arterial beds [72]. When examined in the mouse gastrointestinal tract, EP4 mRNA was 
found to be highly expressed in the gland of the gastric antrum suggesting this subtype is 
involved in PGE2-mediated mucus secretion. Additionally, EP4 has found to be expressed 
in epithelial cells of the intestinal villi [73]. Since EP4 increases cAMP and PGE2 stimulates 
chloride secretion and inhibits salt absorption via production of cAMP, taken together, the 
above findings suggest that EP4 is involved in these processes and consequently PGE2- 
induced diarrhoea [74]. 
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Mice with targeted disruption of the EP4 receptor gene have shown a disturbed perinatal 
closure of the pulmonary ductus arteriosus [75]. Disruption of the EP4 gene results in death 
of most homozygous EP4 -/- neonates within 3 days of birth due to pulmonary congestion 
and heart failure [75]. As noted earlier, EP4 mRNA is present in the ductus and works in 
the dilation of the vessel. EP4 -/- neonates showed full patency of the ductus after birth 
indicating a critical role of EP4 in the ductus. The EP4 receptor ligands may prove useful in 
promoting closure or maintaining patency of the ductus arteriosus in newborns with 
congenital heart disease. Additionally, EP4 deficient mice have shown that PGE2-EP4 
signalling facilitates initiation of skin immune responses by promoting the migration and 
maturation of Langerhans cells. While PGE2 is produced substantially in skin exposed to 
antigen, its role was unclear. Although Langerhans cells express all four EP subtypes, their 
migration to regional lymph nodes was decreased only in EP4-deficient mice and in wtmice 
treated with an EP4 antagonist [76]. Lastly, EP4 deficiency impaired mucosal barrier 
function and induced epithelial loss, crypt damage, and aggregation of neutrophils and 
lymphocytes in the colon. Among the eight prostanoid receptor-deficient mice tested, only 
EP4-deficient mice developed severe colitis with 3% dextran sodium sulfate treatment, 
which induced only marginal colitis in wildtype mice. These studies conclude that EP4 is 
important for maintainence of intestinal homeostasis by protecting mucosal integrity and 
downregulating immune response [77].  
3.9 Cross talk of PGE2 signaling with MAPK pathway 
 
Activation of an oncogene Ras has been found in a wide variety of malignancies which 
induces cell survival, proliferation and transformation by triggering downstream signalling 
pathways such as Raf/MEK/ERKs and PI3K/AKT pathways. The Ras-MAP kinase cascade 
is one of the major intracellular signalling pathways responsible for cell proliferation. 
Constitutively active Ras or MEK upregulates COX-2 expression resulting in increased cell 
proliferation in a variety of cell culture models [78], [79], [80], [81]. It has been shown that, 
NSAIDs and COX-2 selective inhibitors act via Ras-MAPK signalling pathway in inhibiting 
cell proliferation [82], [83], [84]. Many findings support the notion of upregulation of COX-2 
derived PGE2 promoting human cancer cell growth by autoregulation which depends 
primarily on PGE2 induced activation of Ras-MAPK pathway. 
 
Though NSAIDs and COX-2 selective inhibitors are promising, concern over their safety 
over cardio vascular side effects has prompted researchers to look for more effective 
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chemopreventive agents with minimal toxicity. Understanding the molecular mechanisms of 
COX-2 and its downstream targets will help to identify specific molecular targets for 
developing saferagents targeting this pathway. Significant progress has been made in the 
elucidation of PGE2 downstream signalling pathways which mediate the chemopreventive 
effect of NSAIDs [85], [86]. The combined therapy involving multiple agents may allow for a 
lower dose of drug. Taken together, efforts to develop novel chemopreventive agents 
targeting PGE2 pathway with minimal toxicity and to design strategies for combinations of 
different agents targeting multiple pathways may yield significant benefits for cancer 
patients. 
 
In the future, it is important to carefully determine the EP receptor profile in human cancers. 
Taken together, these findings may provide a rationale for the development of EP receptor 
antagonists which may offer an alternative to COX-2 selective inhibitors. 
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4 AIM OF THE STUDY 
Available clinical data has well-established the protective effect of COX-2 inhibition on 
human cancer progression. Despite these encouraging outcomes, the appearance of 
unwanted side effects remains a major hurdle for the general application of COX-2 
inhibitors as effective cancer drugs. Hence, a better understanding of the molecular signals 
downstream of COX-2 is needed for the elucidation of drug targets that may improve 
cancer therapy.  
 
Antagonising the prostaglandin receptors have been shown to be effective in inhibiting 
different cancers. An increasingly large body of evidence indicates that PGE2 promotes 
tumor growth by stimulating EP receptor signalling with subsequent enhancement of 
cellular proliferation, promotion of angiogenesis, inhibition of apoptosis, stimulation of 
invasion/motility, and suppression of immune responses. These findings prompted us to 
elucidate PGE2 signalling pathways and identify PGE2 downstream targets that are 
involved in promoting tumor growth.   
 
Here we aim to show that the COX-2 product prostaglandin E2 (PGE2) acts on cognate 
receptor EP1 to promote the proliferation and migration of NSCLC lung cancer cells. Our 
aims are to establish/check - 
 
• Gene expression profile of EP receptors both at mRNA and protein level in NSCLC 
cells. 
• In vitro effects of pharmacological inhibition of the EP receptors in thymidine 
incorporation assay. 
• In vitro effects of pharmacological inhibition of the EP1 receptor in intra cellular 
calcium and cAMP measurement assay. 
• In vitro effects of pharmacological inhibition of the EP1 receptor in transwell 
migration assay. 
• The downstream pathway to EP1 receptor involved in the proliferation and migration 
of NSCLC cells. 
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5 MATERIALS AND METHODS 
5.1 Materials 
 
Table 4 Materials 
 
Product Company Country 
 
Bovine Serum Albumin Powder Serva Germany 
 
Bovine Serum Albumin solution (2mg/ml) Bio-Rad USA 
cAMP EIA kit Cayman Europe Estonia 
DAPI Dakocytomation USA 
Dc protein assay kit Bio-Rad USA 
DEPC water Roth Germany 
Digest All 2 (trypsin) Vector USA 
Enhanced Chemiluminiscence (ECL) Kit Amersham USA 
Fluorescent mounting medium Dakocytomation USA 
Go Taq PCR Core system I Promega USA 
ImProm-II Reverse transcription system Promega USA 
Milk powder Roth Germany 
N,N’-Methylene-bis-Acrylamide solution, 
Rotiphorese gel 30 
Roth USA 
Protein rainbow marker Amersham USA 
RIPA buffer Santacruz USA 
RNase Away Molecular Bioproducts USA 
Scintillation solution (Rotiszint eco plus) Roth Germany 
SDS solution, 10% w/v Promega USA 
SYBR Green ER qPCR Supermixes 
Universal kit 
Invitrogen USA 
[3H]-thymidine (1mCi/ml) Amersham USA 
Tris-HCl 0.5M, pH 6.8 Amresco SOLON USA 
Tris-HCl 1.5M, pH 8.8 Amresco SOLON USA 
Trizol Invitrogen USA 
Ultra Pure water Cayman Europe Estonia 
 
 
Table 5 Cell culture materials 
 
Cell Culture materials Company Country 
DMEM F12 OptiMEM Invitrogen USA 
HBSS Invitrogen USA 
Fetal Bovine Serum Biowest Germany 
Phosphate Buffer Saline (PBS) PAN Germany 
L-Glutamine PAN Germany 
Penicillin-Streptomycin PAN Germany 
Trypsin EDTA PAN Germany 
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Table 6 Antibodies 
 
Antibodies Company Country 
Mouse anti-GAPDH monoclonal  Sigma-Aldrich USA 
Rabbit anti-EP1 polyclonal antibody Cayman Chemicals USA 
Rabbit anti-EP2 polyclonal antibody Cayman Chemicals USA 
Rabbit anti-EP3 polyclonal antibody Cayman Chemicals USA 
Rabbit anti-EP4 polyclonal antibody Cayman Chemicals USA 
Rabbit anti-pERK polyclonal antibody Santacruz USA 
Rabbit anti-ERK polyclonal antibody Santacruz USA 
Rabbit anti-p21 polyclonal antibody Santacruz USA 
Rabbit anti-p27 polyclonal antibody Santacruz USA 
Rabbit anti-mouse IgG antibody Sigma-Aldrich USA 
Goat anti-rabbit IgG antibody Pierce USA 
Alexa Fluor 488 goat anti-rabbit IgG 
antibody 
Invitrogen USA 
FITC conjugated goat anti-rabbit IgG 
antibody 
Invitrogen USA 
 
 
Table 7 Oligonucleotides 
 
Oligonucleotides 
 
Forward 5’ CTTGTCGGGTATCATGGTGGT 3’ EP1 (151bp) 
Reverse 5’ AAGGGTCCAGGATCTGGTT 3’ 
Forward 5’ CCTCATTCTCCTGGCTATCA 3’ EP2 (187bp) 
Reverse 5’ TCTCAGAACAGGAGGCCTAA 3’ 
Forward 5’ GAGACGGCCATTCAGCTTAT 3’ EP3 (169bp) 
Reverse 5’ CCAGGCGAACAGCTATTAAG 3’ 
Forward 5’ TCTTACTCATTGCCACCTCC 3’ EP4 (160bp) 
Reverse 5’ TCTAGGATGGGGTTCACAGA 3’ 
Forward 5’ CACAGACCGACACAGGCAGC 3’ IP (186bp) 
Reverse 5’ CACCGGCCACGAACATCAGG 3’ 
Forward 5’ GAGTCCGAGGTGGAGATGAT 3’ TP (174bp) 
Reverse 5’ GCGCAAGTAGATGAGCAGC 3’ 
Forward 5’ CAGGAGTCAGACTGTAGGACGAC 3’ PBGD 
Reverse 5’ ACTCTCATCTTTGGGCTGTTTTC 3’ 
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Table 8 Table of Euipments 
 
Equipments 
Equipment Company Country 
BioDoc Analyzer Biometra USA 
Cell culture incubator Hera Cell Heraeus Germany 
Electrophoresis Chamber Biometra USA 
Fluorescence microscope Leica Germany 
Freezer (+4 0C, -20 0C, -80 0C) Bosch Germany 
Infinite 200 microplate reader Tecan Switzerland 
Inolab pH meter WTW Germany 
Light microscope Hund Germany 
Liquid Scintillation Counter Beckmann USA 
Multifuge centrifuge Heraeus Germany 
Mx3000P QPCR system machine Stratagene USA 
Spectrophotometer Nanodrop Technologies USA 
PCR - thermocycler Biometra Germany 
Pipetboy and pipettes Eppendorf USA 
Power supply units Biometra USA 
Precellys 24 homogenizer Bertin Technologies France 
Shaker Biometra USA 
Waterbath for cell culture Medingen Germany 
Waterbath for tubes HLC Germany 
Westernblot Unit Biometra USA 
Vortex machine VWR Germany 
 
 
Table 9 Other materials 
 
Othermaterials Company Country 
Falcon tubes Greiner Bio-One Germany 
PCR tubes Greiner Bio-One Germany 
Glass pipettes Greiner Bio-One Germany 
Cell culture dishes and plates Greiner Bio-One Germany 
96 well microplate Corning USA 
AGFA cronex 5 medical X-ray film AGFA Belgium 
Film cassette Kodak Kodak USA 
Filter tips (10,100, 1000 µL) Nerbe plus Germany 
Gel blotting paper Whatman USA 
Nitrocellulose membrane Pall Corporation USA 
Osmotic minipump (2ml) Durect Corporation USA 
Radiographic film hypersensitive Amersham USA 
Tips (10,100,1000 µl) Eppendorf USA 
Reaction tube Sarstedt Germany 
Real time tube Thermo Fisher USA 
Tissue culture chamber slide BD Falcon USA 
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5.2 Methods 
5.2.1 Cell culture 
 
A549 cells were maintained in DMEM F/12 medium supplemented with 10% FBS, penicillin 
(100 U/ml), streptomycin (0.1 mg/ml), 1% MEM vitamin solution, 2 mM glutamate and 1% 
non-essential amino acids at 37 0C in humidified atmosphere containing 5% CO2. 
 
H1299 cells were maintained in DME M F/12medium supplemented with 10% FBS, 
penicillin (100 U/ml), and streptomycin (0.1 mg/ml) at 37 0C in humidified atmosphere 
containing 5% CO2. 
5.2.2 RNA isolation 
 
Total RNA from tissues or cells was extracted using Trizol reagent according to the 
manufacturer's instructions. 2×106 A549 cells were collected in 1 ml Trizol. Trizol lysates 
were kept at RT for 5 min to dissociate the RNA from histone proteins. Then 0.2 ml of 
chloroform was added and mixed vigorously for 15 sec and centrifuged under 12000 rpm at 
4 0C for 30 min. After that, the transparent upper layer was carefully transferred to a new 
tube and gently mixed with 0.5 ml 2-propanol. After 15 min the mixture was centrifuged at 
12000 rpm at 4 0C for 15 min and the RNA pellet was washed with 1 ml 75% ethanol and 
dried in the air. RNA was dissolved in DEPC-water and stored at -80 0C. The concentration 
and quality of RNA were estimated by Nano Drop spectrophotometer. 
5.2.3 Reverse transcription-PCR (RT-PCR) 
 
cDNA was synthesized by a two-step RT-PCR using ImProm-II™ reverse transcription 
system according to the manufacturer’s instructions. 1 µg RNA in 5 µl reaction A was 
denatured at 70 0C for 5 min, followed by a quick chill for 5 min and addition of 15 µl 
reaction B. The reverse transcription reactions were subjected to cDNA synthesis by firstly, 
annealing at 25 0C for 5 min and incubating at 42 0C for 60 min, followed by thermal 
inactivation of reverse transcriptase at 70 0C for 15 min. The cDNA was stored at -20 0C. 
5.2.3.1 Reaction A component Volume Final concentration 
Table 10 Reaction A component Volume Final concentration 
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Ingredient 
Stock 
Concentrations 
Final Concentrations Volume 
Total RNA 1 µg/ µl 1 µg/20 µl 1 µl 
Oligo(dT)15 primer 0.5 µg/ µl 1 µg/20 µl 2 µl 
Nuclease Free Water   2 µl 
 
5.2.3.2 Reaction B component Volume Final concentration 
Table 11 Reaction B component Volume Final concentration 
 
Ingredient Stock 
Concentrations 
Final 
Concentrations 
Volume 
ImProm-II™ 5X reaction 
buffer 
 1X 4 µl 
MgCl2 25 mM 2.5 mM 2 µl 
dNTPmix 40 mM 2 mM 1 µl 
RNasin® ribonuclease 
inhibitor 
 20 u/20 µl 
 
1 µl 
ImProm-II™ reverse 
transcriptase 
 0.5 u/20 µl 
 
1 µl 
Nuclease-free   6 µl 
Total   15 µl 
 
5.2.4 Quantitative realtime- PCR (qRT-PCR ) 
 
The intron-spanning primer pairs were designed using the Primer3 program and are shown 
in Table 3. Primers were cross checked to insure the specificity by blasting to the whole 
genome. The product size was controlled within the range of 80 bp-150 bp. 
5.2.4.1  qRT-PCR reaction component Volume Final concentration 
Table 12 qRT-PCR reaction component Volume Final concentration 
 
Ingredient Stock 
Concentrations 
Final 
Concentrations 
Volume 
cDNA  0.2 µg/25 µl 2 µl 
MgCl2 25 mM 1 mM 1 µl 
         MATERIALS AND METHODS 
 
29 
ROX 100 µM 25 µM 0.1 µl 
Upstream Primer 10 µM 0.2 µM 0.5 µl 
Downstream primer 10 µM 0.2 µM 0.5 µl 
2 X SYBR® 
GreenER™ 
SuperMix Universal 
buffer 
 1X 12.5 µl 
Nuclease-free water   8.4 µl 
Total    25 µl 
 
qRT-PCR was performed on a Mx3000P® QPCR system using SYBR® GreenER™ qPCR 
SuperMixes Universal kits according to manufacturer’s instructions. For the negative 
control, the cDNA was omitted. The annealing temperature for every gene was 
standardised to 58 0C. By using the MxPro™ QPCR software, a dissociation curve was 
generated for each gene to ensure a single product amplification and the threshold cycle 
(Ct values) for each gene was determined. The comparative 2-∆∆Ct method was used to 
analysis mRNA fold changes between treated and untreated, which was calculated as 
Ratio = 2-(∆Ctcontrol-∆Ct treated) where Ct is the cycle threshold, and ∆Ct (Ct target－Ct reference) is the Ct 
value normalized to the reference gene Porphobilinogen Deaminase (PBGD) obtained for 
the same cDNA sample. Each reaction was run in duplicate and repeated three times 
independently. The calculated 2-∆∆Ct was transformed into a percentage using the control as 
100% to show the mRNA expression difference. 
5.2.4.2 qRT-PCR programm Temperature Time Cycle 
Table 13 qRT-PCR programm Temperature Time Cycle 
 
Step Temperature Time Cycles 
Activation 95 0C  10 min 1 
Denaturation 95 0C  30 Sec 
Annealing 58 0C 30 Sec 
Extension 72 0C 30 Sec 
        
            40  
Denaturating 95 0C 60 Sec 1 
Dissociation curve 55-95 0C indefinite 1 
Soak 4 0C Indefinite 1 
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5.2.5 Western blotting 
5.2.5.1  Protein isolation 
 
Total protein was extracted in RIPA buffer containing 1XTBS, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 0.004% sodium azide. PMSF, proteinase inhibitor 
cocktail and sodium orthovanadate (10µl each in 1 ml RIPA) were added to RIPA buffer 
freshly before use. 250-300 µl of RIPA buffer cocktail was added to 2×106 A549 cells in a 
petridish on ice and cells are scraped out using a scraper and the mixture is taken in to a 
tube. The tube is centrifuged under 12000 rpm for 30 min at 4 0C and the supernatants 
were stored at -80 0C. 
5.2.5.2  Protein concentration analysis 
A series of bovine serum albumin (BSA) solution from 0.2-1.6 mg/ml were used as 
standard. The protein samples were pre-diluted into the range of the standard and the 
concentration of each sample was double estimated by Dc protein assay kit based on the 
method of Bradford using a microplate reader. 
5.2.6 SDS-polyacrylamide (SDS-PAGE) gel electrophoresis 
 
Protein samples of the same concentration were mixed with 5X SDS gelloading buffer at a 
ratio of 4:1 (v/v) and denatured at 100 0C for 5 min. Protein samples (30 µg for pERK, ERK, 
p21, p27 and 15 µg for GAPDH) or rainbow marker were loaded in the wells of 10% SDS-
PAGE gel and run at 100-130 v for 1-2 hours to separate. Buffers are listed as follows. 
5.2.6.1  5×SDS gel-loading buffer component Final concentration 
Table 14 5×SDS gel-loading buffer component Final concentration 
 
Ingredient Final Concentration in mM or Final 
Percentage in V / V or W / V 
Tris-Cl (2 M, pH 6.8) 375 mM 
 
SDS 10% (w/v) 
Glycerol                                                       50% (v/v) 
β-Mercaptoethanol 12.5% (v/v) 
Bromophenol blue 0.02% (w/v) 
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5.2.6.2  Running buffer component Final concentration 
Table 15 Running buffer component Final concentration 
 
Ingredient Final Concentration in mM or Final 
Percentage in V / V or W / V 
Tris-HCl 25 mM 
Glycine 192 mM 
SDS 10% (w/v) or 0.1% (w/v) 
5.2.6.3  Resolving gel (10%) component Volume Final concentration 
Table 16 Resolving gel (10%) component Volume Final concentration 
 
 
Ingredient Final Concentration in mM 
or Final Percentage in V / V 
or W / V 
Volume 
Tris-Cl (1.5 M, pH 8.8) 375 mM 1.5 ml 
Acrylamid 30% (w/v) or 10% (w/v) 2 ml 
SDS 10% (w/v) or 0.1% (w/v) 60 µl 
APS 10% (w/v) or 0.05% (w/v) 30 µl 
TEMED  0.1 % 6 µl 
Double distilled Water  2.4 µl 
Total  6 ml 
5.2.6.4  Stacking gel (6%) component Volume Final concentration 
Table 17 Stacking gel (6%) component Volume Final concentration 
 
Ingredient Final Concentration in mM 
or Final Percentage in V / V 
or W / V 
Volume 
Tris-Cl (0.5 M, pH 6.8) 125 mM 0.625 ml 
Acrylamid 30 % (w/v) or 6 % (w/v) 0.5 ml 
SDS 10% (w/v) or 0.1% (w/v) 25 µl 
APS 10% (w/v) or 0.05% (w/v) 12.5 µl 
TEMED  0.1 % 2.5 µl 
Double distilled Water  1.34 µl 
Total  2.5 ml 
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5.2.7 Immunoblotting 
 
The proteins separated on the SDS-PAGE were transferred to nitrocellulose membrane 
using an electrophoretic transfer machine. After being soaked in blocking buffer for 1 h at 
RT, membranes were probed with specific primary antibodies (rabbit polyclonal anti- EP1 
antibody,1:1000; rabbit polyclonal anti-EP2 antibody, 1:000; rabbit polyclonal anti-EP3 
antibody; rabbit polyclonal anti-EP4 antibody, 1:000; rabbit polyclonal anti-phospho-ERK 
antibody, 1:000; rabbit polyclonal anti-ERK antibody, 1:000; mouse monoclonal anti- 
GAPDH antibody, 1:5000) overnight at 4 0C. After wash with TBST for 3 times, horse radish 
peroxidase (HRP) conjugated secondary antibodies (anti-rabbit, 1:50000; anti-mouse, 
1:50000) were applied to the membranes respectively for 1 h at RT. After washing, the 
blots were developed with an enhanced chemiluminescence (ECL) kit for 5 min and 
chemiluminescence signal was captured on an X-ray film. Each blot was repeated 3 times 
or more independently with representative blots shown. 
5.2.7.1  Blotting buffer Final concentration 
Table 18 Blotting buffer Final concentration 
 
Ingredient Final Concentration in mM or Final 
Percentage in V / V or W / V 
Tris-HCl 50 mM 
Glycine 40 mM 
Methanol 20% (v/v)  
 
5.2.7.2  TBST buffer (pH 7.6) component Final concentration 
Table 19 TBST buffer (pH 7.6) component Final concentration 
 
Ingredient Final Concentration in mM or Final 
Percentage in V / V or W / V 
Tris-HCl 20 mM 
NaCl 137 mM 
Tween 0.1% (v/v)  
 
5.2.7.3  Blocking buffer component Final concentration 
Non-fat milk 5% (w/v) in TBST 
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5.2.8 Immunocytochemistry 
 
A549 cells were grown on 8-well chamber slides 24 hours. Cells are fixed with the ice-
chilled acetone-methanol mixture (1:1) for 10 min at 4 0C. After washing with PBS, the fixed 
cells were sequentially incubated with blocking buffer (3% BSA in PBS）for 1 h at RT, and 
then the primary antibody against EP1, EP2, EP3 and EP4 (1:300 in blocking buffer) for 1 h 
at RT or overnight at 4 0C. After the primary antibody incubation, cells were washed 5 times 
with PBS and subjected to FITC-conjugated anti-mouse or Alexa Fluor® 488 anti-rabbit 
secondary antibody (1:1000 in PBS) for 1 h at RT in dark. Then cells were washed 5 times 
with PBS and counterstained for nuclei with DAPI (500 ng/ml in blocking buffer) for 3 min. 
After washing with PBS, the upper chamber was removed and the slide was covered with a 
cover slide using the fluorescent mounting medium. The staining was visualized using a 
Leica DMLA fluorescence microscope and Leica QWin imaging software. The wells without 
primary antibodies were negative controls. 
5.2.8.1 EP receptor inhibitors 
 
SC-51322, AH-6809, L-798106 and L-161982 were used as selective EP inhibitors for EP 
1, EP2, EP3 and EP4 respectively. 
5.2.9 Intracellular Calcium Measurement Assay 
 
Intracellular Ca2+ concentrations were measured by determining the ratio of the 
fluorescence of fura 2 after excitation at 340 nm and 380 nm (Grvnkiewicz et al.. 1985). 
Cells on glass coverslips were loaded with the dye by incubation in Hepes Ringer solution 
containing fura 2-AM (5 µM) and bovine serum albumin (0.1%) for 60 min at 37 0C. After 
incubation, cells were washed twice with Hepes Ringer solution and then mounted in a cell 
chamber (36 0C) before starting fluorescence measurements in presence and absence of 
EP1 receptor specific agonists and antagonists. Experiments were performed using a 
system from Till Photonics (Martinsried, Germany) with monochromator (Polychrome V), 
camera (PCO Sensi Cam), and software (TILLvisION v3.3) as well as microscope from 
Olympus (IX70 WI, Olympus, Hamburg, Germany).  
 
The cells formed a confluent monolayer and a fixed square diaphragm was used to limit the 
fluorescence measurement to a field of view which typically contained 60-80 cells. The cells 
were excited at 340 nm and 380 nm every second, and emitted fluorescence signal were 
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detected. Cells were marked and ratio of fluorescence after excitation at 340 nm and 
380 nm were calculated after background subtraction.   
 
Solutions: The Herpes Ringer solution used during fluorescence measurements contained 
(mM): NaCl (136.4), KCl (5.6), CaCl2 (2.2), MgCl2 (1): Glucose (11), HEPES (10) (pH 7.4). 
Agonists and antagonists were added to Hepes Ringer solution. Stock solutions of both 
agonists and antagonists were frozen until use. 
5.2.10 cAMP enzyme immunoassay (EIA)  
 
Intracellular cAMP content of A549 cells was determined by a competitive non-acetylated 
EIA, using a specific cAMP EIA Kit according to the manufacturer's instructions. At the end 
of culture, cells were washed twice with PBS and lysed in 0.1 M HCl at RT for 20 min. The 
lysates were collected and centrifuged under 12000 rpm for 30min at 4 0C. The supernatant 
was transferred to a new tube and stored at -80 0C. The protein concentration was 
estimated by the Dc protein assay as described before and equalized to 0.3 µg/ µl for use. 
50 µl protein samples or standard solutions were incubated in dark with 50 µl tracer and 50 
µl antibody overnight at 4 0C. After washing 5 times, the plate was incubated with Ellman’s 
solution for 90-120 min at RT with gentle shaking. The plate was measured at a wavelength 
of 405 nm and the concentration was calculated by the ready-made Cayman EIA Double 
workbook. The standard curve was made as a plot of the %B/B0 value (%Bound/Maximum 
Bound) vs concentration of a series of known standards using a linear (y) and a log (x) axis. 
Using the 4- parameter logistic equation obtained from the standard curve, the cAMP 
concentration of samples was determined and given as nmol/mg protein. Each sample was 
performed in duplicate and repeated twice. 
5.2.11 Proliferation assay 
 
A549 cell proliferation was achieved by [3H]-thymidine incorporation assay. A549 cells 
(around 1×104 cells/well) were seed on 48- well plates and the following day the medium 
was substituted with DMEM/F12 containing 0.1% FBS with or without EP inhibitors to 
render the cells quiescent. After serum starvation, cells were induced to cell cycle re-entry 
by 10% FBS together with different EP inhibitors for 24 h. The concentration of EP 
inhibitors used for proliferation assay was pre-proved for EP selectivity according to the 
previous experiments. During the last 4 h of agonist stimulation, 10 µl [3H]-thymidine (0.01 
µCi/ ml) was added to 250 µl medium to incorporate into the DNA. Cells were then washed 
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twice with 500 µl chilled HBSS, fixed with 250 µl ice-cold methanol for 15 min at 4 0C and 
then precipitated by 250 µl 10% trichloroacetic acid (TCA) for 15 min at 4 0C. After washing 
with water, samples were finally lysed in 0.1 M NaOH, transferred into 4 ml scintillation 
solution and counted by a beta counter giving a CPM value. All labeling was performed on 
quadruplicate cultures and repeated twice independently. The proliferation of A549 cells 
under agonist stimulation is shown as a percentage taking the CPM of unstimulated A549 
cells under 0.1% FBS as 100%. 
5.2.12 Transwell Invitro Migration Assay 
 
We determined the ability of SC-51322, an EP1 receptor specific inhibitor to inhibit the 
migration of A549 cells in vitro by Transwell migration assay. A549 cells were starved for 
24 h before seeding 20,000 cells per well in the upper chamber of the transwell containing 
serum free DMEM F-12 medium, where as the lower chambers contain three different 
subsets of DMEM F-12 medium with 10% FCS, 10% FCS+10 µM PGE2, 10% FCS+10 µM 
PGE2 + SC-51322. The transwell chamber was incubated at 37 0C for 6 h to allow the 
migration of cells through the membrane into the lower chamber. Media was removed using 
a gentle suction. Cells were then washed with 1X PBS and fixed to the membrane using 
methanol wash for 2-3 minutes. After the fixation, cells were stained for 1-2 minutes with 
haematoxylin which gives purple color to the cells. After the staining, the transwell was 
cleaned from inside with a cotton swab to remove the unmigrated cells and then we 
quantified the number of migrated cells that reached the lower part of the transwell filter 
membrane using a phase contrast microscope counting in six random fields. 
5.2.13 MTT cytotoxicity assay 
Cell viability/cytotoxicity were assessed by the MTT assay using a CellTiter 96AQ kit 
according to the manufacturer’s instructions. Briefly, the cells were plated in 96-well plates 
and allowed to attach for 6 h, and then cultured under serum-free conditions with various 
concentrations of SC 51322 for 48 h. The number of surviving cells was determined by 
measuring the absorbance at 560 nm of the dissolved formazan product after addition of 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt 
for 1 h. All of the experiments were carried out in triplicate.  
5.2.14 Statistical analysis 
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Data are expressed as mean and standard error of mean (SEM). All statistical analysis was 
performed with Student’s t-test between two groups or with oneway ANOVA and Newman-
Keuls post-hoc test for multiple comparisions, as appropriate. Difference between groups is 
considered significant when P < 0.05. 
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6 RESULTS 
6.1   Expression profile of EP receptors in A549 cells 
 
Expression profile of EP receptors in A549 cells was done by quantitative RT-PCR and by 
western blotting. EP1 and EP3 receptors are less expressed compared to EP2 and EP4 in 
A549 cells at mRNA level (Figure 4a) and also at protein level (Figure 4b, 4c) 
 
 
   (a) 
 
 
 
 
 
 
    
     
   (b)                                                  (c)  
                       
 
 
 
 
 
 
 
Figure 4: mRNA and Protein expression profile of EP receptors in A549 cells 
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(a) m-RNA expression profile of EP receptors in A549 cells (b) Representative immunoblots against EP 
receptors with GAPDH as a loading control (C) Densitometric quantification of EP receptors’ expression in 
A549 cells is shown as a ratio by normalization to GAPDH in a bar graph. 
6.2 Cellular localisation of EP receptors in A549 cells  
 
The cellular localisation of all EP receptors in A549 cells by using immunocytochemistry. 
Immunofluorescence staining showed a predominant expression of EP1 and EP2 receptors 
both on cell membrane and nucleus where as EP3 and EP4 receptors are confined mostly 
to cytoplasm (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Immunocytochemical staining of EP receptors in A549 cells.  
 
Cellular localization of EP1, EP2, EP3 and EP4 receptors in A549 cells, shown by representative 
immunofluorescence. Red (EP1-4, FITC-conjugated); Blue (nuclei, DAPI). Scale 20 µm. 
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6.3 Anti proliferative effect of EP inhibitors on A549 cells 
 
We further tested the contribution of all EP receptors to the proliferation of A549 cells by 
using receptor specific antagonists. A549 cell proliferation was reduced significantly by EP1 
receptor inhibitor SC-51322 (1, 5 & 10 µM) (Figure 6a) and EP4 receptor inhibitors, L-
161,982 (5 & 10 µM) (Figure 6d) where as EP2 and EP3 receptor inhibitors, AH-6809 and L 
-798106 respectively (Figure 6b & 6c) have no affect on proliferation of A549 cells. Basing 
on these experiments we concluded that among the EP receptors, only EP1 and EP4 
receptors, contribute to the proliferation of A549 cells.                                                              
     
(a)            (b) 
 
 
 
 
 
 
    (c)                      (d) 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Anti-proliferative effect of EP receptor inhibitors on A549 cells 
A549 cells were starved for 24 h and EP receptor specific inhibitors (SC-51322, EP1 inhibitor; AH-6809, EP2 
inhibitor; L-798106, EP3 inhibitor; L-161982, EP4 inhibitor) were applied respectively for 24 hours. [3H]-
thymidine incorporation was performed in the last 4 h of experiment. Results represent the mean ± SEM for 
n=3 experiments done in duplicate; **p ≤ 0.01 and *** p ≤ 0.001 compared with control. 
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6.4 Expression profile of EP receptors in H1299 cells 
In order to substantiate the findings from A549 cell line, Expression profile of EP receptors 
in H1299 cells was done by western blotting. EP1 and EP2 receptors exhibited low 
expression as compared to EP3 and EP4 in H1299 cells as observed by western 
blotting(Figure 7a), followed by densitometric analysis (Figure 7b). 
   (a)                        (b) 
 
 
 
 
 
 
 
 
Figure 7:  EP receptor expression profile in H1299 cells  
Relative protein levels of EP receptors in H1299 cells and (a) representative immunoblots against EP 
receptors with GAPDH as a loading control (b) Densitometric quantification of EP receptors’ expression in 
H1299 cells is shown as a ratio by normalization to GAPDH in a bar graph. 
6.5 Cellular localisation of EP receptors in H1299 cells  
 
We further confirmed our western blot data by investigating the cellular localisation of all EP 
receptors in H1299 cells by using immunocytochemistry. Immunofluorescence staining 
showed a predominant expression of EP1 and EP2 receptors both on cell membrane and 
nucleus where as EP3 and EP4 receptors were confined mostly to cell membrane (Figure 
8). 
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Figure 8: Immunocytochemical staining of EP receptors in H1299 cells. 
 
Cellular localization of EP1, EP2, EP3 and EP4 in H1299 cells, shown by representative 
immunofluorescence. Green (EP1-4, Alexa 488/555 - conjugated); Blue (nuclei, DAPI). Staining is shown in a 
400×magnification. 
 
6.6 Anti proliferative effect of EP1 inhibitor on H1299 cells 
 
Similar to our studies in A549 cell line, we investigated the contribution of EP receptors to 
the proliferation of H1299 cells by using EP receptor specific antagonists. H1299 cell 
proliferation was reduced significantly by EP1 receptor inhibitor, SC-51322 (Figure 9) and 
EP4 receptor inhibitors, L-161,982 at 10 µM concentrations. Where as EP2 and EP3 
receptor inhibitors, AH-6809 and L -798106 respectively have no affect on proliferation of 
H1299 cells that EP1 and EP4 receptors contribute the most to proliferation of H1299 cells.  
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Figure 9: Anti-proliferative effect of EP receptor inhibitors on H1299 cells. 
H1299 cells were starved for 24 hours and EP receptor specific inhibitors (SC-51322, EP1 inhibitor; AH-6809, 
EP2 inhibitor; L-798106, EP3 inhibitor; L-161982, EP4 inhibitor) were applied respectively for 24 hours. [3H]-
thymidine incorporation was performed in the last 4 h of experiment. Results represent the mean ± SEM for 
n=3 experiments done in duplicate; *** p ≤ 0.001 compared with control. 
6.7 Inhibiton of EP1 receptor does not modulate intra cellular cAMP 
accumulation  
To determine the secondary messenger downstream to EP1 receptor, we measured 
intracellular cAMP levels in presence and absence of SC-51322 (EP1 receptor inhibitor).                   
 
 
 
 
 
 
 
 
 
Figure 10: Pharmacological inhibition of EP1 receptor does not alter intracellular 
cAMP levels 
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A549 cells were starved for 24 h and treated with 10% FCS. After the treatment, Intra cellular cAMP levels of 
A549 cells were measured in presence of SC-51322 using Tecan spectrophoto meter. SC-51322 could not 
alter the intracellular cAMP levels at 5 µM & 10 µM. 
Intracellular cAMP levels of A549 cells did not show any significant changes after inhibiting 
with SC-51322 (Figure 10). 
6.8 Inhibiton of EP1 receptor modulates intra cellular calcium levels  
 
The EP1 receptor agonist, 17-PGE2 induced changes in Ca2+ in cultured A549 cells. Figure 
9 shows the effects of a maintained bath application of 17-PGE2 on intra cellular Ca2+, in 
A549 confluent cultures. The cells were superfused twice, first with a normal Hepes Ringer 
solution twice to yield a steady baseline in the resting Ca2+, then to one with agonists 
added. The responses shown are for the agonists from different coverslips of cells of the 
same passage. The shape of the responses for PGE2 and 17-PGE2 is similar; there is an 
initial large intra cellular Ca2+ spike (raising the intra cellular Ca2+, by about 300-400 nM), 
followed by a decaying oscillatory phase. This phase consists of a series of spikes with 
diminishing amplitudes and a periodicity initially of 20-30 set, but increasing to 40- 100 set 
as the response gradually is damped. About 66% of experiments gave an oscillatory 
response to PGE2 and 17-PGE2 during sustained agonist application.  
 
While an initial rapid spike was observed consistently in all experiments, the number of 
oscillations which followed showed some variations; In-addition, in a few experiments with 
17-PGE2, oscillations did not appear to be damped out entirely but continued on until the 
end of the experiment (10 min). In contrast to PGE2 and 17-PGE2, 10 µM of SC-51322 
(EP1 antagonist) elicited virtually no effect on intra cellular Ca2+.         
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Figure 11: Inhibiton of EP1 receptor modulates intra cellular calcium levels of A549 
cells  
A549 cells were treated with 500µM of 17-P-T-PGE2, increased intracellular calcium was observed (Figure 
11a&b) where as no increased intracellular calcium was observed when A549 cells were treated with 10 µM 
concentrations of EP1 inhibitor, SC-51322 (Figure 11a&b) and DMSO control has shown no effect on intra 
cellular calcium levels. Results represent the mean ± SEM for n=3 experiments done in duplicate; *** p ≤ 
0.001 compared with DMSO control. 
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6.9 Pharmacological Inhibiton of EP1 receptor modulates ERK phosphorylation 
A549 cells were serum starved for 24 h and treated with the EP1 inhibitor, SC-51322 for 30 
minutes and 24 h. SC-51322 reduced the activation of ERK in A549 cells when treated for 
30 minutes but showed no significant effect when A549 cells were treated for 24 h (Figure 
12).  
                (a)                                                                            
                                                                                          
 
 
 
          
(b)   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Inhibition of phosphorylation of ERK by EP1 receptor inhibitor. 
A549 cells were starved for 24 hours and treated with EP1 inhibitor, SC-51322 for 30 m and 24 h. Proteins 
were isolated from the treated A549 cells and immunoblotted against phospho-ERK and total ERK, with 
GAPDH as a loading control. Results represent the mean ± SEM for n=3 experiments done in duplicate; *** p 
≤ 0.001 compared with control. 
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6.10 Pharmacological inhibition of EP1 receptor inhibits A549 cell migration. 
A549 cells were serum starved for 24hours and then stimulated with 10% FCS in presence 
and absence of 10µM PGE2 and SC-51322 (EP1 receptor inhibitor) in a transwell migration 
chamber.  
     
 
            
 
 
 
 
 
 
 
(e)  
 
 
 
 
 
 
 
 
Figure 13: EP1 receptor antagonist inhibits A549 cell migration. 
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Migration of A549 cells towards 10% FCS was observed (Figure 13 b). 10 µM PGE2 along with 10% FCS 
attracted more number of cells compared to 10% FCS alone (Figure 13 c) where as, very less number of 
migrated cells were observed when cells were pre-treated with 10 µM of SC-51322 (Figure 13 d). DMSO/No 
FCS control can be seen with almost no migrated cells (Figure 13 a) and a representative graph can be seen 
in Figure 13e. Results represent the mean ± SEM for n=3 experiments done in duplicate; *** p ≤ 0.001 
compared with control. 
 
6.11  EP1 inhibitor has no cytotoxicity on A549 cells 
Cell viability/cytotoxicity were assessed by the MTT assay using a CellTiter 96AQ kit 
according to the manufacturer’s instructions. Briefly, the cells were plated in 96-well plates 
and allowed to attach for 6 h, and then cultured under serum-free conditions with various 
concentrations of SC 51322 for 48 h. The number of surviving cells was determined by 
measuring the absorbance at 560 nm of the dissolved formazan product after addition of 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt 
for 1 h.  
 
 
 
 
 
 
 
 
 
 
Figure 14:  Cytotoxicity of EP1 inhibitor on A549 cells 
No cytotoxic effects were observed when A549 cells were treated with 5 µM, 10 µM, 15 µM 
and 20 µM of EP1 receptor specific inhibitor SC-51322.  
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7  DISCUSSION 
A very high expression of COX-2 is frequently found in many types of cancer, including 
lung cancers and is usually associated with poor prognosis and short survival [87]. 
Identification of four subtypes of the PGE receptors (EP1, EP2, EP3 & EP4) has made it 
possible to analyze their effects on human cancer cells. Cancer cells express multiple PGE 
receptor subtypes and that each subtype may be linked to different actions of PGE2. So, it 
is important to know the role of each receptor individually to identify them as potential 
targets for cancer treatments. 
 
Here, we examined the expression pattern at mRNA and protein level of all four EP 
receptors in A549 and H1299 cells (adenocarcinoma cell lines) using qRT-PCR and 
western blots. All four receptors exhibited strong mRNA expression in the cell line (Figure 
4a). In line with this result, all the EP receptors showed protein expression (Figure 4b, 4c & 
7a, 7b). Additionally, immuno-cytochemical stainings showed EP3 and EP4 receptors to be 
confined mostly to cell membrane, where as EP1 and EP2 receptors were found to be 
expressed in both cell and nuclear membrane (Figure 5 & 8). Finding these receptors on 
nuclear membranes might have a role in transferring message received from cell 
membrane to the nucleus, and would be a subject for investigation in future.  
 
The importance of EP1 receptors in carcinogenesis has been studied using diverse 
models. In EP1 deficient mice, tumor incidence, tumor multiplicity and tumor volume were 
decreased in the AOM-induced colon carcinogenesis model [88]. Antagonisisng EP1 
receptor through diet reduced abberant crypt foci formation in mouse [89], [90]. Increase in 
EP1 positive cells was observed in mice skin after prolonged UV treatment [91]. In UVB-
induced mouse papillomas and SCCs and human SCCs, EP1 mRNA expression and 
protein levels were increased 2 ~ 10 fold [70], [92]. In glioma cells, SC51089 and AH6809 
(EP1 receptor antagonists) suppressed cell proliferation by 50% [93]. Though EP1 is not 
expressed in normal mouse mammary glands, an increase in EP1 expression is observed 
in mammary tumors [94].  In rat hepatocytes an increase in DNA synthesis was observed in 
a PLC dependent manner when they were treated with 17-phenyl-trinor-PGE2 and 
sulprostone, EP1 agonists [95]. In human breast cancer cells, EP1 receptor antagonist 
treatment significantly suppressed VEGF-C protein production [96]. PGE2 mediated 
upregulation was inhibited by EP1 receptor siRNA in colon tumor cells [97]. 
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In lymphangiogenesis, EP1 is also known to play an important role via VEGF-C. Treatment 
with SC19220, an EP1 antagonist or an EP1 antisense oligonucleotide inhibited PGE2 
mediated VEGF-C mRNA and protein induction effectively.  Su, Shih et al in 2004 have 
proved that EP1 mediated VEGF-C induction is mediated through Src and Her2/Neu 
activation [98]. 
 
The EP2 receptor was shown to play a significant role in the protumorigenic action of PGE2 
in skin tumor development. The EP2 knockout mice produced significantly fewer tumors 
and reduced tumor incidence compared with wildtype mice in a two-stage skin 
carcinogenesis model [99]. Furthermore, UV-irradiated mice lacking EP2 receptors exhibit 
decreased proliferation and a poor capacity for epidermal hypertrophy in response to UV 
injury. Interestingly, in a chronic irradiation model, these animals were protected from tumor 
formation, developing 50% fewer tumors than wildtype controls. Despite this capacity to 
protect against tumorigenesis, animals lacking EP2 receptors grew tumors that were larger 
in size, with a more aggressive phenotype. This was found to be associated with greater 
quantities of active matrix metalloproteinases than keratinocytes expressing the EP2 
receptor, thereby enhancing the invasive potential of EP2-/- cells.   
 
Furthermore, one study showed that disruption of EP2 decreases the size and number of 
intestinal polyps in APC∆716 mice [100]. The lack of EP2 in MMTV-COX-2 transgenic mice 
strongly suppressed COX-2–induced effects such as precocious development of the 
mammary glands. The development of mammary hyperplasia in multiparous female mice 
suggests disruption of EP2 signalling as a chemopreventive approach to breast cancer 
[101]. 
 
The EP3 receptor is the one EP receptor that has consistently not been directly involved in 
tumor production. Examination of mRNA expression levels in colon tissue of mice, rats and 
human showed a marked reduction in the EP3 receptor in colon cancer compared to 
normal mucosa [102-103]. Expression of EP3 mRNA was detected in only one of eleven 
colon cancer cell lines tested and treatment of that one cell line with an EP3 agonist 
decreased viable cell numbers by 30%. Immunohistochemical staining demonstrated rat 
EP3 protein expressed in normal epithelium and some parts of small carcinomas but 
absent in large carcinomas of the colon, suggesting EP3 is downregulated during colon 
cancer progression. While deficiency in EP3 had no effect on ACF development, an 
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increase in AOM-induced colon carcinoma was found in EP3 knockout mice suggesting 
EP3 may not impact early stages as greatly as later stages of colon carcinogenesis. As 
noted, EP2 and EP4 stimulate adenylate cyclase, whereas EP3 inhibits cAMP formation, 
suggesting a possible suppressive role against colon carcinogenesis.  
 
In addition to CRC, EP1, EP2 and EP4 receptors were elevated, whereas EP3 receptor 
levels were decreased in mammary tumors from COX-2/MMTV mice [104]. In contrast to 
these findings, a recent study reported EP3 receptor signaling to play an important role in 
tumor-associated angiogenesis [105]. In this context, implanted tumor growth (sarcoma-
180, Lewis lung carcinoma) and tumor-associated angiogenesis were markedly reduced in 
EP3 null mice. Moreover, EP3 antagonists reduced tumor size in wildtype but had no effect 
on EP3 null mice. Using the sponge implantation model, it was shown that VEGF 
expression is significantly reduced in EP3 null mice compared to wildtype mice.  
 
There is a growing appreciation for the EP4 receptor as an important transducer of PGE2 
signaling, leading to cell invasion and motility during tumorigenesis. The EP4 receptor is 
over expressed in several different cancers including colon and rectal cancers [106]. 
Interestingly, constitutive expression of EP4 receptor promotes proliferation and 
anchorage-independent growth, demonstrating that the EP4 receptor may also be a key 
regulator of tumor progression [107]. This receptor has been shown to have the highest 
affinity towards pro-tumorigenic PGE2 ligand in ligand binding assays ([108-109]. EP4 
receptor signaling also appears to be important for cell movement and motility during 
development. Studies in the zebra fish show that the EP4 receptor transduces PGE2 
signals to regulate appropriate speed of cell migration during gastrulation, demonstrating 
that regulation of cell motility by EP4 receptor signaling is evolutionarily conserved [110].  
 
Signaling mediated through the EP4 receptor in colorectal carcinogenesis is constantly 
being appreciated. PGE2 was shown to stimulate the proliferation and motility of LS174T 
adenocarcinoma cells through the EP4 receptor dependent activation of PI3K/AKT 
signaling [111]. Whereas PGE2 inhibits apoptosis in human Caco-2 adenocarcinoma cells 
through an EP4 dependent pathway [112]. Furthermore, premalignant ACF formation in 
EP4 deficient mice following AOM treatment is suppressed as compared to those in EP4 
wild type mice. This study also showed a reduction in colon adenomatous polyp formation 
in mice wild-type for the EP4 receptor but treated with the EP4 receptor antagonist ONO-
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AE2-227 [113]. Treatment with another EP4 antagonist, ONO-AE3-208, decreased liver 
metastases after intrasplenic injection of MC26 colon cancer cells [114]. In addition, in vitro 
studies indicate that PGE2/EP4 receptor signaling via ERK activation promotes tumorigenic 
behavior in colon cancer cells [115]. Another avenue that PGE2/EP4 signaling has been 
shown to contribute towards carcinogenesis is the Wnt signaling pathway. Interestingly, 
PGE2 stimulated EP4 receptor can transcriptionally activate a transcription factor Tcf/Lef (T 
Cell Factor/Lymphoid Enhancer Factor) via a PI3K mediated pathway. This transcription 
factor regulates the expression of Cyclin D1 which is a key protein in cell cycle progression 
in colon carcinogenesis [116], [117]. In addition, the EP4 receptor was determined to be a 
genetic risk factor in both ulcerative colitis as well as Crohn’s disease in a study that used 
genome-wide associations to understand molecular pathways leading to Inflammatory 
Bowel Disease (IBD) [118]. 
 
A reduced number of azoxymethane (AOM)-induced aberrant crypt foci were observed in 
EP4 receptor deficient mice and antagonizing EP4 receptor also resulted in a similar 
manner in Min mice [113]. In one of the lung cancer models, Lewis lung carcinoma (LLC) 
cells, a reduced metastasis has been observed when they were treated with an EP4 
receptor antagonist [114]. Mouse mammary tumor cells treated with EP4 antagonists also 
had reduced metastasis in vivo [119].  
 
Cancer cells divide uncontrollably increasing both in size and number. So, pharmacological 
interventions to prevent the rate of proliferation of cancer cells have always been of great 
interest. PGE2 signaling through the EP4 receptor has previously been associated with 
NSCLC. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction 
of integrin-linked kinase with the involvement of EP4 receptor and Sp1 protein [120]. 
Ritzenthaler JD et al [121] in 2009 have shown that NSCLC cells express PPARbeta/delta 
protein and that treatment with a selective PPARbeta/delta agonist, GW501516, stimulated 
the expression of EP4 and induced NSCLC cell proliferation. In agreement to previous 
studies, L-161982 an EP4 receptor specific inhibitor prevented the A549 and H1299 cells 
from proliferation in thymidine incorporation assays (Figure 6 & 9). 
 
Though In lung cancer, especially in NSCLC, prostanoid receptor EP4 is known to play role 
in growth and metastasis, no other EP receptor has been shown to be involved in 
pathology of NSCLC.  
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Here, we studied the effect of EP receptor specific inhibitors on the rate of proliferation of 
both A549 and H1299 cells.  SC-51322 an EP1 receptor specific inhibitor showed inhibitory 
effects at 1 µM, 5 µM and 10 µM on A549 cells (Figure 6) where as, it showed inhibitory 
effects at 10 µM on H1299 cells (Figure 9). Both AH-6809 (EP2 receptor specific inhibitor) 
and L-798106 (EP3 receptor specific inhibitor) showed no inhibitory effect on A549 and 
H1299 cell proliferations (Figure 6 & 9). So, from the above results it is a new finding to 
know the role of EP1 receptor in the proliferation of NSCLC cell lines besides an already 
known role of EP4 receptor.  The cytotoxicity of SC-51322 on proliferation of A549 cells has 
been established using MTT assay. MTT assay shows no cytotoxic affects on A549 cells 
when they were treated with different concentrations of SC-51322 (Figure 14). From this 
MTT assay we can conclude that reduced proliferation values of A549 cells, is truly EP1 
receptor mediated and not by formation of dead cells due to its cytotoxicity. 
 
PGE2 signals through four G-protein-coupled cell surface receptors, termed as EP1, EP2, 
EP3, and EP4. The EP1 receptors are coupled to Gαq protein and increase cytosolic Ca2+ 
levels in response to PGE2 [109]. Both EP2 and EP4 receptors increase intracellular cyclic 
AMP (cAMP) levels by activating adenylyl cyclise by coupling to Gαs, whereas Gαi-coupled 
EP3 receptors inhibit cAMP formation [109]. Thus, the effects of PGE2 on cell proliferation 
appear to be mediated by its overall second messenger response [122]. To further decipher 
the role of EP1 receptor in proliferation of A549 cells, they were treated with 500 µM of 17-
P-T-PGE2 which elicits in an increase in intra cellular calcium where as no increase of 
calcium was observed when cells were pre-treated with 10 µM of SC-51322 for 30 min 
(Figure 11a & b). This experiment establishes the role of calcium in EP1 mediated 
proliferation of A549 cells.    
 
Involvement of ERK pathway and prostanoid signaling in the progression and metastasis of 
many types of cancers has been well documented previously [123], [124]. Recent literature 
suggests a crosstalk of these two pathways in the malignant cancers [125]. In the present 
study, we demonstrated a concentration and time-dependent activation of ERK in A549 
cells in presence of 17-P-T-PGE2 (EP1 receptor specific agonist) at various concentrations. 
A selective EP1 receptor antagonist, SC-51322 suppresses 17-P-T-PGE2 induced ERK 
phosphorylation after 30 min of incubation. In this context, our results suggest that selective 
targeting of EP1 receptor with EP1 receptor antagonists such as SC-51322 may be 
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beneficial to block PGE2 effects on cell proliferation of human lung cancer cells. We plan to 
evaluate the efficacy of SC-51322 analogs in vivo.  
 
Cancer cells divide uncontrollably and start to invade other parts of the body by a process 
called metastasis. It is a very important phase of cancer development both in terms of 
treatment and survival of patients. Once cancer gets metastasized, it becomes hard to treat 
them. Mortality in patients with cancer principally results from the metastatic spread of 
cancer cells to distant organs [126].  
 
PGE2 has been reported to stimulate the motility of A549 cells via EP4-dependent 
stimulation of betaArrestin1, and c-Src which mediates cancer cell migration [127]. It has 
also been shown that, PGE2 enhances the migration of chondrosarcoma cells by 
increasing alpha2beta1 integrin expression through the EP1/PLC/PKCalpha/c-Src/NF-
kappaB signal transduction pathway [128]. In oral cancer cells, prostaglandin E2/EP1 
signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and 
cell motility and a cross-talk between the COX-2/PGE(2)/EP(1) and EGFR/c-Met signaling 
pathways has been reported which coordinately regulate human HCC cell invasion [129-
130]. These findings led us to investigate the contribution of EP signaling in mediating 
migration of A549 cells.  
 
A549 cells, after 24 hours of serum starvation, significantly started moving towards 10% 
FCS in a transwell migration chamber (Figure 13b). The number of cells moving towards 
10% FCS had increased in presence of 10 µM of 17-P-T-PGE2 in the media (Figure 13e). 
Where as, SC-51322 had significantly reduced the number of migrating cells towards a 
stimulus of 10% FCS and 10 µM 17-P-T-PGE2 (Figure 13d & e). Though, SC-51322 
inhibited migration of A549 cells in transwell migration assay, it needs to be further 
investigated in vivo to completely establish a role of EP1 receptor in metastasis of NSCLC.  
 
        Conclusion: 
Our studies, which are in agreement with several other reports, indicate an important role 
for EP1 receptor in proliferation of NSCLC for the following reasons:  
 
1. Reduced proliferation of A549 & H1299 cells in response to the SC-51322  
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2. Pre-treatment of A549 cells with AH-6809 (EP2 antagonist) and L-798106 (EP3 
antagonist) did not have any effect on PGE2-induced ERK phosphorylation.  
 
3. 17-phenyltrinor PGE2 (a selective EP1 agonist), induced ERK phosphorylation. 
 
4. L-161,982 (EP4 receptor antagonist) and SC-51322 (EP1 receptor antagonist) at 
concentrations of 10µM abrogated 17-P-T-PGE2-induced ERK phosphorylation.  
 
5. SC-51322 has also inhibited release of intracellular calcium when stimulated with 
17-P-T-PGE2 establishing a EP1/PLC/ERK pathway in proliferation of A549 cells. 
SC-51322 has not decreased cAMP levels in A549 (Figure 10) which is in 
agreement to our speculation. 
 
In summary, the data presented in these studies strengthen an important role for the EP1 
receptor in NSCLC. Since PGE2 is frequently elevated in NSCLC, signalling mediated by 
the EP1 receptor could represent an important step in the clonal evolution of lung cancer 
epithelial cells during the adenoma-carcinoma sequence and contribute to malignancy. 
Finally, in light of the recent side-effects associated with the use of COX-2 inhibitors, our 
studies support the notion that the inhibition of EP1 receptor signalling events may 
represent an alternative therapeutic target for the prevention and treatment of NSCLC. 
 
Proposed pathway of prostanoid signalling in NSCLC proliferation 
 
1. 17-P-T-PGE2 binds specifically to cell membrane bound prostanoid receptor EP1. 
2. EP1 receptor upon binding to 17-P-T-PGE2, elicits an increase in intra cellular 
calcium. 
3. Increased intra cellular calcium activates ERK resulting in an increase of pERK 
which up on translocation to nucleus results in cellular proliferation, metastasis and 
angiogenesis. 
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Figure15: Proposed Mechanism of Action 
 
Outlook 
We need to further substantiate our results by performing 
 
• gene silencing experiments using siRNA / shRNA to EP1 receptor  
• dissection of more downstream effectors to EP1 receptor mediated signaling 
• experiments with in vivo lung cancer models and 
• human tissue samples 
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receptors playing role in progression and metastasis of lung cancer were measured by 
western blotting. New directions to the project are under investigation.  
 
Presentations:  
 
• Oral presentations at MBML retreats on the topics of “Role of prostanoid signaling in 
Pulmonary Arterial Hypertension (PAH)” (2009 & 2010) and “Role of prostanoid signaling in 
lung cancer (2011)”.   
 
• Poster presentation on a topic titled “Role of prostanoid signaling in lung cancer” at 103rd 
annual meeting of American Association for Cancer Research (AACR) held during 30th 
March – 4th of April 2012 in Chicago, USA. 
 
Publications:  
Current project is under the process of submission. 
 
1. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. 
 
    Eur Respir J. 2010 Oct;36(4):808-18. Epub 2010 Jun 7. 
    Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, Schirok H, Stasch JP,   
    Ghofrani HA,Weissmann N, Grimminger F, Seeger W, Schermuly RT. 
    University of Giessen Lung Center, Giessen, Germany.  
 
Previous Job Experience 
 
Associate Research Scientist (Feb’06 – Sep’08) 
Worked as an Associate Research scientist at Advinus Therapeutics Pvt.Ltd (A TATA 
Enterprise), Pune, India.  
Job responsibilities: 
As an associate scientist, I was involved in planning and executing research protocols. I was 
responsible to analyze the results and report/document to the groups (assay and molecular 
biology groups of Drug Discovery wing) involved in Phase I studies.    
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Job profile: 
Cloning and expression of target genes in bacterial and mammalian systems. Tranfection 
of DNA in to mammalian cells (Eg: HEK; Human Embryonic Kidney and CHO; Chinese 
hamster Ovary), characterization of clones by calcium and cAMP assays and single cell 
selection of clones.  
 
My responsibilities involved screening for NCEs (New Chemical Entities) with therapeutic 
value in metabolic and inflammatory disorders using cell based GPCR assays, by 
measuring intracellular calcium flux (FLEX STATION II) and cyclic AMP assays. My work 
also involved screening of therapeutic small molecules against rheumatoid arthritis, a 
disabling and painful inflammatory condition, which can lead to substantial loss of mobility 
due to pain and joint destruction. During the course of this work, I have used extremely 
sensitive cell based assays and cell free assays like radio-ligand binding assay in order to 
establish a robust screening assay system for high throughput NCE screening.  
 
My job responsibilities also included purification & characterization of targeted proteins from 
both mammalian and bacterial systems [Characterization - Km & specific activity 
determination], Studying expression profile of different genes at m-RNA level in different 
tissues and cell-lines by RT-PCR. 
 
Junior Research Fellow (Oct’04 – Feb’05) 
 
• Worked as a Junior Research Fellow at TIFR (Tata Institute of Fundamental Research), 
Mumbai, India. 
Job responsibilities:  
 
• Determination of LhX1 gene expression at mRNA level in different regions of the brain in 
11.5 day mouse embryo by Non-radio labeled in-situ hybridization. 
• Genotyping of mice colonies by tail DNA PCR for LhX1 +/+ & +/- strains. 
 
MSc Thesis:  [January’04 - July ‘04] 
A Seven month training at Tansgenic and Gene Knock-Out Laboratory, Centre for Cellular 
and Molecular Biology (CCMB), Hyderabad on a project titled “Structural analysis of 
Regulatory Mechanism in High Level Expression of Casein Genes in Mice” under the 
supervision of Prof.Dr. Satish Kumar. 
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Academic Profile 
 
M.Sc – Micro Biology 
University : Barkatullah University 
                  University Teaching Department – Bhopal, India. 
Percentage : First class (65%) 
Duration : 2002 – 2004.  
 
B.Sc (Microbiology, Bio-chemistry and Chemistry) 
University  : Nagarjuna Univesity 
                           T.J.P.S. College, Guntur, A.P, India. 
Percentage       : First class (75%) 
Duration            : 1999 – 2002. 
 
HSSC  (Botany, Zoology, Chemistry and Physics) 
Board   :S.R.K.S.Junior College (Guntur) 
     Board of Intermediate Education, Hyderabad, A.P, India. 
Percentage  : First class (73.7%) 
Duration  : 1996 – 1998.               
 
 SSC (Senior Secondary School) 
 Board  : S.M.P.School, Guntur. 
     Board of secondary education, Hyderabad, A.P, India. 
 Percentage : First class (80.4%) 
 Duration : 1996. 
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         (Pavan Kumar Pamarthi) 
